Compositions and methods for treating celiac sprue disease

Abstract

polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of seq ID NO: 1, are provided, wherein (a) the polypeptide degrades a PFQPQLPY (seq ID NO: 140) peptide and/or a PFPQPQQPF (seq ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from seq ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.

Description

CROSS REFERENCE

This application is a U.S. national phase of International Application No. PCT/US2016/036356, filed on Jun. 8, 2016, which claims priority to U.S. Provisional Application No. 62/172,557, filed Jun. 8, 2015, both of which are incorporated by reference herein in their entirety.

BACKGROUND

Celiac sprue is a highly prevalent disease in which dietary proteins found in wheat, barley, and rye products known as ‘glutens’ evoke an immune response in the small intestine of genetically predisposed individuals. The resulting inflammation can lead to the degradation of the villi of the small intestine, impeding the absorption of nutrients. Symptoms can appear in early childhood or later in life, and range widely in severity, from diarrhea, fatigue and weight loss to abdominal distension, anemia, and neurological symptoms. There are currently no effective therapies for this lifelong disease except the total elimination of glutens from the diet. Although celiac sprue remains largely underdiagnosed, its' prevalence in the US and Europe is estimated at 0.5-1.0% of the population. In addition to celiac spine, a significant fraction of the population is thought to suffer from the condition of non-celiac gluten sensitivity (NCGS), which is caused by the ingestion of gluten but is mechanistically distinct from celiac disease, though the symptoms are frequently indistinguishable from those of celiac sprue. The identification of suitable naturally-occurring enzymes as oral therapeutics for celiac disease and NCGS is difficult due to the stringent physical and chemical requirements to specifically and efficiently degrade gluten-derived peptides in the harsh and highly acidic environment of the human digestive tract. Since gluten peptides initiate the immune response immediately upon entering the intestines, it is imperative that any oral enzyme therapeutic for celiac disease break down these immunogenic gluten regions in the gastric compartment, thereby preventing these gluten peptides from causing intestinal damage due to inflammation.

SUMMARY OF THE INVENTION

In one aspect, the invention provides polypeptides comprising an amino acid sequence at least 75%, 80%, 85%, 90%, 95%, or more identical to the amino acid sequence of SEQ ID NO: 1, wherein

• • (a) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and
  • (b) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 463, 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 105, 171, 172, 173, 174, and 456.

In one embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 463, 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, and 461. In another embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/T/V, 319A, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, 461R, and 463A/L/M/Q/R/T/V. In a further embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 1 at 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or more residues selected from the group.

In one embodiment, the polypeptide comprises amino acid changes from SEQ ID NO: 1 at residues 399 and 449, such as amino acid changes 399Q and 449Q. In another embodiment, the polypeptide comprises amino acid changes 358S and 463T. In a further embodiment, the polypeptide comprises amino acid changes 262E, 269T, 354Q, 358S, 399Q, 449Q, and 463T. In another embodiment, the polypeptide comprises amino acid changes 319A, 368F, 399Q, 449Q, and 463T. In a further embodiment, the polypeptide comprises amino acid changes 262E, 269T, 270V, 354Q, 358S, 399Q, and 449Q. In a still further embodiment, the polypeptide comprises amino acid changes 262E, 269T, 320M, 354Q, 358S, 399Q, 449Q, and 463T. In another embodiment, the polypeptide comprises amino acid changes 319A, 320M, 368F, 399Q, 449Q, and 463T. In one embodiment, the polypeptides comprise an amino acid change from SEQ II) NO: 1 at one or more amino acid positions selected from the group consisting of 105, 171, 172, 173, 174, and 456, such as amino acid changes 105H; 171R A, or S; 172R, A, or S; 173R or S, 174S, and/or 456V.

In another aspect, the invention provides polypeptide comprising an amino acid sequence at least 75%, 80%, 85%, 90%, 95%, or more identical to the amino acid sequence of SEQ ID NO: 71, wherein

• • (a) residue 278 is Ser, residue 78 is Glu, and residue 82 is Asp; and
  • (b) the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 274, 32, 73E, 79, 80, 81, 130A, 165E/Q/R/Y, 169S/Q/T, 179F/Q, 210, 213, 217, 235, 260, 267, and 272.

In one embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 274, 32, 73E, 79, 80, 81, 130A, 165E/Q/R/Y, 169S/Q/T, 179F/Q, 210, 213, 217, 235, 260, and 272.

In one embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81A/T/V, 130A, 165E/Q/R/Y, 169S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, 272R, and 274A/L/M/Q/R/T/V. In a further embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 71 at 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more residues selected from the group. In one embodiment, the polypeptide comprises amino acid changes from SEQ ID NO: 71 at residues 210 and 260, including but not limited to amino acid changes 210Q and 260Q In another embodiment, the polypeptide comprises amino acid changes 169S and 274T. In a further embodiment, the polypeptide comprises amino acid changes 73E, 80T, 165Q, 169S, 210Q, 260Q, and 274T. In another embodiment, the polypeptide comprises amino acid changes 130A, 179F, 210Q, 260Q, and 274T. In a further embodiment, the polypeptide comprises amino acid changes 73E, 80T, 81V, 165Q, 169S, 210Q, and 260Q. In a still further embodiment, the polypeptide comprises amino acid changes 73E, 80T, 320M, 165Q, 169S, 210Q, 260Q, and 274T. In one embodiment, the polypeptide comprises amino acid changes 130A, 131M, 179F, 210Q, 260Q, and 274T. In another embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 71 at amino acid position 267, including but not limited to 267V.

In another embodiment, the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2-42, 44-60 and 72-112, and 114-130 and 150-155. In a further embodiment, the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2-42, 55-60 and 72-112, and 125-130 and 150-155.

In one embodiment, the polypeptides of the invention may further comprise a histidine tag at the C-terminus of the polypeptide. In another embodiment, the histidine tag comprises a cleavable histidine tag In a specific embodiment, the cleavable histidine tag may comprise or consist of the amino acid sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139). In another embodiment, the cleavable histidine tag may comprise the amino acid sequence X_NPQ(L/Q)PX_NHHHHHH (SEQ ID NO: 131), wherein X_N is an linker of between 1-25 amino acid residue. In a further embodiment, the cleavable histidine tag may comprise the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ ID NO: 132).

In another aspect, the invention provides nucleic acids encoding the polypeptide of any embodiment of the invention. The invention further provides nucleic acid expression vector comprising the nucleic acids of the invention. The invention further provides recombinant host cells comprising the nucleic acid expression vectors of the invention. The invention also provides pharmaceutical composition, comprising the polypeptide, nucleic acid, nucleic acid expression vector, and/or the recombinant host cell of any embodiment of the invention, and a pharmaceutically acceptable carrier.

In another aspect, the invention provides methods for treating celiac sprue or non-celiac gluten sensitivity (NCGS), comprising administering to an individual with celiac sprue or NCGS an amount effective to treat the celiac sprue or NCGS of a polypeptide or pharmaceutical composition of any embodiment of the invention. In one embodiment, the polypeptide or the pharmaceutical composition is administered orally.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Kuma030 is capable of rapidly and effectively degrading the immunogenic regions of gluten in gastric conditions. (A) The amount of gluten detected after a 60 minute incubation period with the indicated concentrations of either EPB2 and SCPEP (at a 1:1 ratio), Kuma010, or Kuma030 in gastric conditions, as measured by ELISA using the G12 antibody. The starting concentration of gluten was 10 mg mL-1 (10,000 ppm). Note that the Y-axis is plotted on a logarithmic scale. (B) The amount of gluten detected at 5 or 30 minutes after incubation with EPB2 and SCPEP at 400 μg mL-1, or Kuma030 at 10, 100, or 400 μg mL-1. The starting concentration of gluten was 10 mg mL-1. Samples were normalized to the amount of gluten measured after incubation with pepsin alone. ES: a 1:1 weight ratio of EPB2 and SCPEP. Asterisk indicates that the amount of gluten was below the level of quantification (5 ppm). (C) HPLC trace of full-length peptide (grey dotted lines) breakdown products (black lines) of the immunodominant peptides from gliadin (W02-E07, W03-E07, 33mer), hordein (B08-E2E7), or secalin (R11-E4E7). The bottom of the figure shows the amino acid sequence of the 33mer peptide, position of known immunogenic epitopes (horizontal lines), location of the Kuma030 cleavage sites as determined by LCMS (vertical lines), and elution peaks of the resulting breakdown products (grey arrows) Immunodominant peptides displayed the following breakdown patterns: B08-E2E7: PQQPIPQ∥QPQTYPQ∥Q (SEQ ID NO: 61); R11-E4E5: QPFPQ∥QPEQHPQ∥QP (SEQ ID NO:62), W02-E7: LQPFPQPQ∥LPYPQPQ (SEQ ID NO: 63); W03-E7: QPFPQPQ∥QPFPWQP (SEQ ID NO: 64). All peptide masses and elution times were confirmed by LCMS. Note that although the undigested W03-E07 peptide eluted at approximately the same time as the W03-E07 breakdown fragments, these are separate peaks, as determined by LCMS. aAU, arbitrary absorbance units.

FIG. 2. Gliadin treated with Kuma030 loses it immunostimulatory potential. (A-E) Purified gliadin was treated with Kuma030 at the specified concentration for 60 minutes at pH 4.0 at 37° C. in the presence of 0.6 mg mL-1 pepsin. After the gastric phase, the pH of the samples was increased, and samples were treated with chymotrypsin and TG2. Samples were then exposed to T cell lines from patients #1 (A), #2 (B), #3 (C), #4 (D), or #5 (E), in the presence of autologous irradiated B cell lines, and IFN-γ was measured by ELISA. Phytohemagglutenin (PHA) and a peptic-tryptic digest of gliadin (PT-Gliadin) were included as positive controls. Incubation of T cell lines with antigen-presenting cells in the absence of antigens acted as a negative control. (F) T cell stimulatory epitopes recognized by the T cells used in this assay and the predicted Kuma030 cleavage sites within these epitopes. Predicted Kuma030 cleavage sites are shown by a vertical line Cleavage sites are predicted based on Kuma030 activity on gliadin peptides as presented in FIG. 1F (from top to bottom: SEQ ID NOs: 141, 142, 141, 142, 143, 144, 141, 142, 143, 144, 145, 145, 146, 145).

FIG. 3. Kuma030 is not toxic to T cells. Possible toxic effect of enzyme-treated gliadin was assessed in human peripheral blood mononuclear cells (PBMCs) from healthy donors that were stimulated with the mitogen phytohemagglutinin (PHA). (a,b) IFN-g production of T cells from healthy donor #1 (A) or healthy donor #2 (B). (C,D) T cell proliferation of T cells from healthy donor #1 (C) or healthy donor #2 (D). No effect on IFN-g production or cell proliferation was observed, except in the proliferation of healthy donor #2 (but not in the production of IFN-g). Since the reduction of PHA-stimulated cell proliferation was the same irrespective of the enzyme treatment, we conclude that this effect was not due to toxicity of the samples.

FIG. 4. Kuma030 efficiently degrades gluten in complex food matrices. (A) The amount of gluten remaining in whole wheat bread after a 30 minute incubation with either Kuma030 or a 1:1 combination of EPB2:SCPEP at the indicated enzyme concentrations. The starting concentration of gluten was 10,000 ppm. Note both axes are plotted on a logarithmic scale. (B) The amount of gluten remaining in a wheat beer after incubation with the indicated concentrations of either a 1:1 ratio of EPB2:SCPEP, or Kuma030, at 37° C. or 4° C., at S, 15, or 60 minutes. Gluten was detected using the G12 ELISA method.

FIG. 5. Comparison of 26-mer and 33-mer degradative abilities of Kuma010, Kuma020, Kuma030, Kuma040, and Kuma050. Enzymes were incubated at 2 μg mL⁻¹ with 1 mg mL⁻¹ of either the 33mer peptide (FIG. 5A) or the 26mer peptide (FIG. 5B) for 60 minutes. Samples were taken at the indicated timepoints, and the concentrations of peptide breakdown products were measured. Breakdown products were: from the 33mer peptide (SEQ ID NO: 69), LPYPQPQF (SEQ ID NO: 137); from the 26mer peptide (SEQ ID NO: 70), QPYPQ (SEQ ID NO: 147). Activities are graphed as the ratio of the appropriate m/z signal to that of the internal standard.

FIG. 6. The G320M mutation improves activity by 2-4 fold. Shown is activity in degradation of immunogenic epitopes DQ2.5-glia-α1a (contains PQL) (FIG. 6A), and DQ2.5-glia-ω1 (contains PQQ) (FIG. 6B). Samples were taken at the indicated timepoints, and the concentration of peptide breakdown product PFPQPQ (SEQ ID NO: 148) was measured. Activities are graphed as the ratio of the appropriate m/z signal to that of the internal standard.

FIG. 7. P171R and H172R mutations do not appear to negatively affect activity. Enzymatic activities are shown for enzyme variants Kuma030, Kuma031, Kuma032, Kuma040, Kuma041, and Kuma042 on the immunogenic gliadin epitope DQ2.5-glia-ω1a. Samples were taken at the indicated timepoints, and the concentration of peptide breakdown product PFPQPQ (SEQ ID NO: 148) was measured. Activities are graphed as the ratio of the appropriate m/z signal to that of the internal standard. All enzymes were purified by anion exchange.

FIG. 8. Kuma062 demonstrates a higher level of enzymatic activity than Kuma030 or Kuma040. Shown is activity on the immunogenic gliadin epitope DQ2.5-glia-ω1. FIG. 8A: detection of full-length DQ2.5-glia-ω1; FIG. 8B: detection of the PFPQPQ (SEQ ID NO: 148) breakdown product. Samples were taken at the indicated timepoints, and the concentration of either full-length peptide, or breakdown product PFPQPQ (SEQ ID NO:148), was measured. Activities are graphed as the ratio of the appropriate m/z signal to that of the internal standard.

DETAILED DESCRIPTION

All references cited are herein incorporated by reference in their entirety. Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, Calif.), “Guide to Protein Purification” in Methods in Enzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, 2^nd Ed (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, Tex.).

As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. “And” as used herein is interchangeably used with “or” unless expressly stated otherwise.

As used herein, amino acid residues are abbreviated as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gin; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

All embodiments of any aspect of the invention can be used in combination, unless the context clearly dictates otherwise.

In a first aspect, the present invention provides polypeptides comprising an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, wherein

• • (a) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and
  • (b) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456. In one embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, and 463.

SEQ ID NO: 1 (Kuma 011)
Kuma011
(SEQ ID NO: 1)
MSDMEKPWKE(10)GEEARAVLQG(20)HARAQAPQAV(30)DKGPVAGD

ER(40)MAVTVVLRRQ(50)RAGELAAHVE(60)RQAAIAPHAR(70)EH

LKREAFAA(80)SHGASLDDFA(90)ELRRFADAHG(100)LALDRANVA

A(110)GTAVLSGPDD(120)AINRAFGVEL(130)RHFDHPDGSY

(140)RSYLGEVTVP(150)ASIAPMIEAV(160)LGLDTRPVAR(170)

PH(172)FRMQRRAE(180)GGFEARSQ(188)A

A(190)APTAYTPLDV(200)AQAYQFPEGL(210)DGQGQCIAII

(220)E(221/32)LGGGYDEAS(230/41)LAQYFASLGV(240/51)

PAPQVVSVSV(250/61)DGASNQPTGD(260/71)PK(262/73)

GPDGE(267/78)V(268/79)E(269/80)L(270/81)D(271/82)

IEVAGALAP(280/91)GAKFAVYRAP(290/101)DTTAGFLDAI

(300/111)TTAIHDPTLK(310/121)PSVVSISWS(319/130)G

(320/131)PEDSWTSAAI(330/141)AAMNRAFLDA(340/151)

AALGVTVLAA(350/161)AGDS(354/165)GSTG(358/169)GE

(360/171)QDGLYHVH(368/179)FP(370/181)AASPYVLACG

(380/191)GTRLVASGGR(390/201)IAQETVWND(399/210)G

(400/211)PD(402/213)GGAT(406/217)GGGV(410/221)

SRIFPLPAWQ(420/231)EHAN(424/235)VPPSAN(430/241)

PGASSGRGVP(440/251)DLAGNADPA(449/260)T(450/261)

GYEVVIDGEA(460/271)T(461/272)VI(463/274)GGTS

(467/278)AVAPLFAALVARINQKLGKAVGYLNPTLYQLPADVFHDITE

GNNDIANRAQIYQAGPGWDPCTGLGSPIGVRLLQALLPSASQPQP

Kuma010 as reference herein is identical to Kuma011, but includes the histidine tag sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139) at its C-terminus.

Bold face residues represent the N-terminal portion present in the unprocessed polypeptide; non-bold faced font represents residues present in the processed version of the polypeptide. The numbers in parentheses indicate residue number; where there are two numbers separated by a “/”; the number on the left is the residue number in the unprocessed version, and the number on the right is the residue number in the processed version. SEQ ID NO:1 is the unprocessed version of Kuma011; SEQ ID NO:71 is the processed version of Kuma011.

As disclosed in the examples that follow, polypeptides according to this aspect of the invention are improved polypeptides for use, for example, in treating celiac sprue. The polypeptides are modified versions of either the processed version or the preprocessed version of the polypeptide of SEQ ID NO: 1 (KUMAMAX™, hereinafter referred to as Kuma010), which was disclosed as useful for treating celiac sprue (WO2013/023151). Polypeptides for treating celiac sprue are capable of degrading proline (P)- and glutamine (Q)-rich components of gluten known as ‘gliadins’ believed responsible for the bulk of the immune response in most celiac sprue patients. The polypeptides of the present invention show superior activity in degrading peptides having a PQLP (SEQ ID NO: 65) or PQQP (SEQ ID NO: 66) motif (such as PFPQPQLPY (SEQ ID NO: 67) and/or PFPQPQQPF (SEQ ID NO: 68)), which are substrates representative of gliadin) at pH 4 compared to Kuma011 and other polypeptides disclosed as useful for treating celiac sprue (WO2015/023728), and/or are shown to improve production of the polypeptides. Thus, the polypeptides of the invention constitute significantly improved therapeutics for treating celiac sprue.

Thus, the polypeptides of the invention degrade a PFPQPQLPY (SEQ ID NO: 67) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) peptide at pH 4, as well as LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 69) and/or FLQPQQPFPQQPQQPYPQQPQQPFPQ (SEQ ID NO: 70).

Polypeptides of the first aspect of the invention comprise preprocessed versions of the polypeptide enzymes of the invention.

In a second aspect, the invention provides polypeptides comprising an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:71, wherein

• • (a) residue 278 is Ser, residue 78 is Glu, and residue 82 is Asp; and
  • (b) the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 32, 73E, 79, 80, 81, 130A, 131, 165E/Q/R/Y, 169S/Q/T, 179F/Q, 210, 213, 217, 235, 260, 267, 272, and 274. In one embodiment, the polypeptide comprises an amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 32, 73E, 79, 80, 81, 130A, 131, 165E/Q/R/Y, 169S/Q/T, 179F/Q, 210, 213, 217, 235, 260, 272, and 274.

Polypeptides of the first aspect of the invention comprise processed versions of the polypeptide enzymes of the invention, and also degrade a PFPQPQLPY (SEQ ID NO: 67) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) peptide at pH 4, as well as LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 69) and/or FLQPQQPFPQQPQQPYPQQPQQPFPQ (SEQ ID NO: 70).

As used herein, “at least 75% identical” means that the polypeptide differs in its full length amino acid sequence by 25% or less (including any amino acid substitutions, deletions, additions, or insertions) from the polypeptide defined by SEQ ID NO: 1 or SEQ m NO: 71.

In various embodiments of any aspect of the polypeptides of the invention, the polypeptides comprise or consist of an amino acid sequence at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence according to SEQ ID NO: 1 (preprocessed) or SEQ ID NO:71 (processed).

The polypeptide of any aspect of the polypeptides of the invention may comprises an amino acid change from SEQ ID NO: 1 or SEQ ID NO:71 at 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or all 24 (depending on the embodiment) of the recited residues.

In one embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises one or more amino acid changes from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/T/V, 319A, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, 461R, and 463A/L/M/Q/R/T/V. As used throughout, the number indicates the residue number in the SEQ ID NO:1 or SEQ ID NO:71 polypeptide sequence, and the single letter amino acid abbreviations to the right of the number indicate the possible amino acid substitutions compared to the amino acid residue present at that position in SEQ ID NO:1 or 71.

In another embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises amino acid changes from SEQ II) NO: 1 at residues 399 and 449. In one embodiment, the polypeptide comprises amino acid changes 399Q and 449Q.

In a further embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises 358S and 463T. These polypeptide are extensively characterized in the examples that follow, as exemplified by the polypeptide designated as Kuma020 and variants thereof.

In one embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises 262E, 269T, 354Q, 358S, 399Q, 449Q, and 463T. These polypeptide are extensively characterized in the examples that follow, as exemplified by the polypeptide designated as Kuma030 and variants thereof. In another embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises 319A, 368F, 399Q, 449Q, and I463T. These polypeptide are extensively characterized in the examples that follow, as exemplified by the polypeptide designated as Kuma040 and variants thereof. In a further embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises 262E, 269T, 270V, 354Q, 358S, 399Q, and A449Q. These polypeptide are extensively characterized in the examples that follow, as exemplified by the polypeptide designated as Kuma050 and variants thereof. In one embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises 262E, 269T, 320M, 354Q, 358S, 399Q, 449Q, and 463T. These polypeptide are extensively characterized in the examples that follow, as exemplified by the polypeptide designated as Kuma060 and variants thereof. In a still further embodiment of the polypeptides of the first aspect of the invention, the polypeptide comprises, 319A, 320M, 368F, 399Q, 449Q, and 463T. These polypeptide are extensively characterized in the examples that follow, as exemplified by the polypeptide designated as Kuma070 and variants thereof.

In another embodiment of the polypeptides of the first aspect of the invention, the polypeptides comprise an amino acid change from SEQ ID NO: 1 at one or more amino acid positions selected from the group consisting of 105, 171, 172, 173, 174, and 456. In one embodiment, the amino acid change is 105H; 171R A, or S; 172R, A, or S; 173R or S, 174S, and/or 456V. In another embodiment, the amino acid change is 171R, 172R, and/or 456V.

In one embodiment of the polypeptides of the second aspect of the invention the polypeptide comprises one or more amino acid change from SEQ ID NO: 71 at one or more residues selected from the group consisting of 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81A/T/V, 130A, 165E/Q/R/Y, 169S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, 272R, and 274A/L/M/Q/R/T/V. In another embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises amino acid changes from SEQ ID NO: 71 at residues 210 and 260. In a further embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises amino acid changes 210Q and 260Q. In one embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises 169S and 2741. (Kuma 20 genus) In another embodiment of the polypeptides of the second aspect of the invention the polypeptide comprises 73E, 80T, 165Q, 169S, 210Q, 260Q, and 274T. (Kuma 30 genus) In a further embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises 130A, 179F, 210Q, 260Q, and 274T. (Kuma 40 genus) In a still further embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises 73E, 80T, 81V, 165Q, 169S, 210Q, and 260Q. (Kuma 50 genus) In one embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises 73E, 80T, 320M, 165Q, 169S, 210Q, 260Q, and 274T. (Kuma 60 genus) In another embodiment of the polypeptides of the second aspect of the invention, the polypeptide comprises 130A, 131M, 179F, 210Q, 260Q, and 274T. (Kuma 70 genus) In a still further embodiment of the polypeptides of the second aspect of the invention, the polypeptides comprise an amino acid change from SEQ ID NO: 71 at one or more amino acid positions selected from the group consisting of 267. In one embodiment, the amino acid change is, 267V.

In a further embodiment of the polypeptides of any aspect of the invention, the polypeptides further comprise a histidine tag at the C-terminus of the polypeptide, to facilitate isolation of the polypeptide. Any suitable histidine tag can be used; in one embodiment the tag is linked to a TEV protease cut sit (ENLYFQS) (SEQ ID NO: 149) to allow for its efficient removal with 1EV protease after purification, for example, the tag may comprise or consist of the amino acid sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139). In another embodiment, the histidine tag is a cleavable histidine tag, permitting easier removal of the His-tag. In one embodiment, the cleavable histidine tag comprises the amino acid sequence X_NPQ(L/Q)PX_NHHHHHH (SEQ ID NO: 131), wherein X_N is an linker of between 1-25 amino acid residues. In one non-limiting example, the cleavable histidine tag comprises the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ ID NO: 132).

In one embodiment of any aspect of the polypeptides of the invention, amino acid substitutions compared to SEQ ID NO: 1 or SEQ ID NO: 71 may comprise one or more of the substitutions noted in Tables 1 or 2. Substitutions at these positions were found to be generally well-tolerated (i.e. generally result in minor to no effects on activity), and in some cases to increase the activity of the polypeptides of the invention by no more than 20%.

TABLE 1

Possible Amino Acid Substitutions at Position Relative to Kuma10.
Residue number
(preprocessed/
processed) Residue

221/32     D, N, Q, H
261/72     A, R, N, D, C, Q, E, G, H, I, L, K, M,
           S, T, W, Y, V
262/73     A, R, N, D, C, Q, E, G, H, I, L, M, F, T, W, Y, V
264/75     A, N, D, C, Q, E, G, S, T, Y
266/77     A, C, S
268/79     S, T
269/80     L, T
270/81     A, R, N, D, C, Q, E, G, I, K, S, T, V
317/128    A, N, C, G, T, V
318/129    A, R, N, D, C, Q, E, G, H, L, K, M, F,
           S, T, Y, V
319/130    A, N, D, C, Q, H, M, T
320/131    A, R, N, D, C, Q, K, M, S
350/161    N, D, C, G, S, T
351/162    G, S
353/164    A, R, N, C, Q, E, G, I, K, M, S, T, V
354/165    A, R, N, D, C, Q, E, G, H, L, K, M, F,
           T, W, Y
358/169    A, S, N, Q, T
368/179    A, R, N, C, Q, E, G, K, M, F, S, T, W, Y
397/208    A, C, F, Y
399/210    Q, N
402/213    Q, N, S
406/217    S
424/235    K
446/257    G, S
448/259    A, R, N, D, C, Q, E, G, H, I, L, K, M,
           F, S, T, W, Y, V
449/260    Q, E, G, N
456/267    A, N, D, C, Q, E, G, H, L, S, T, V
461/272    R
463/274    A, R, N, D, C, Q, E, G, H, L, K, M, F,
           S, T, W, Y, V
464/277    A, N, D, C, S,
466/279    D, C, G, S

In another embodiment of any aspect of the polypeptides of the invention, amino acid substitutions compared to SEQ ID NO: 1 or SEQ ID NO: 71 may comprise one or more of the substitutions noted in Table 2.

Residue number
(preprocessed/
processed) Residue

221/32     D, N, Q, H
261/72     S
262/73     A, R, N, D, Q, E, G, L, M, T
264/75     A
268/79     S, T
269/80     L, T
270/81     A, T, V
317/128    A, T
319/130    A
354/165    A, R, N, D, Q, E, K, T, Y
358/169    A, S, N, Q, T
368/179    A, N, D, Q, E, S, T
402/213    Q, S
406/217    S
424/235    K
446/257    S
449/260    Q, N, A
456/267    V
461/272    R
463/274    A, R, Q, L, M, T, V

In another embodiment of any aspect of the polypeptides of the invention, amino acid at each residue of the polypeptides of the invention may be as noted in Table 3, which lists all of the possible mutations at each position in the polypeptide enzymes as predicted by computational mutagenesis analysis. As described in the examples that follow, mutations were tested at each position found in the active site (residues 261-264, 266-267, 270, 317-320, 350-354, 368, 397, 403-404, 446, 448, 456, and 463-468) using degenerate primers to test the effects of various amino acid substitutions on activity; those that did not interfere with activity can be incorporated in the polypeptides of the invention, as reflected in Table 3.

TABLE 3
Possible Amino Acids at Residues Relative to Kuma 010
Full
Length	Mature	Amino Acid Possibilities
190	1	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
191	2	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, PRO, SER, THR, TRP, VAL
192	3	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, PRO, SER, TRP, TYR
193	4	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
194	5	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
195	6	ALA, ASN, CYS, GLN, HIS, LEU, MET, PHE, THR, TYR
196	7	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, THR, TRP, TYR
197	8	ALA, GLY, PRO, SER
198	9	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
199	10	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
200	11	ALA, ASN, ASP, CYS, GLY, ILE, SER, THR, VAL
201	12	ALA, CYS, GLY, SER
202	13	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
203	14	ALA, GLY, SER
204	15	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TYR
205	16	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
206	17	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TYR, VAL
207	18	ALA, CYS, GLN, GLU, GLY, LYS, PRO, SER, THR, TRP
208	19	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
209	20	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
210	21	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LEU, MET, SER, THR, VAL
211	22	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, THR, TYR
212	23	GLY
213	24	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
214	25	GLY
215	26	ALA, ASN, ASP, CYS, GLN, GLU, GLY, SER, THR
216	27	ALA, ASN, ASP, CYS, GLN, GLY, SER, THR, VAL
217	28	ALA, CYS, ILE, LEU, SER, THR, VAL
218	29	ALA, GLY, SER
219	30	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, MET, SER, THR, VAL
220	31	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, SER, THR, VAL
221	32	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, SER, THR, VAL
222	33	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, SER, THR, VAL
223	34	ALA, ARG, ASN, ASP, CYS, GLU, GLY, LYS, MET, SER
224	35	GLY
225	36	GLY
226	37	ALA, ARG, ASN, ASP, CYS, GLU, GLY, HIS, LEU, PHE, SER, THR, TRP, TYR
227	38	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LYS, MET, SER
228	39	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
229	40	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
230	41	ALA, GLY, SER
231	42	ALA, ASN, ASP, CYS, GLN, GLU, GLY, LEU, SER, THR
232	43	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
233	44	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
234	45	ALA, ASN, CYS, GLY, HIS, PHE, SER, TYR
235	46	ALA, ASN, ASP, CYS, HIS, MET, PHE, SER, THR, TRP, TYR
236	47	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
237	48	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
238	49	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, MET, SER, THR, VAL
239	50	GLY
240	51	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, SER, THR, TYR, VAL
241	52	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
242	53	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PRO, SER, THR, VAL
243	54	ALA, GLY, PRO, SER
244	55	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
245	56	ALA, ASN, CYS, GLY, SER, THR, VAL
246	57	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
247	58	ALA, ARG, ASP, CYS, GLY, ILE, LYS, MET, PRO, SER
248	59	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
249	60	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, PRO, SER, THR
250	61	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, SER, THR, VAL
251	62	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TYR, VAL
252	63	ASN, ASP, GLY, SER
253	64	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, THR, TRP
254	65	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
255	66	ALA, ARG, ASN, ASP, CYS, MET, SER, THR
256	67	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
257	68	ALA, ARG, ASN, CYS, GLN, GLU, GLY, ILE, LYS, MET, PRO, SER, THR, VAL
258	69	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
259	70	GLY
260	71	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
261	72	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PRO, SER, THR, TRP, TYR, VAL
262	73	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
263	74	GLY
264	75	ALA, ASN, ASP, CYS, GLN, GLU, GLY, PRO, SER, THR, TRP
265	76	ALA, ASN, ASP, CYS, GLN, GLU, GLY, SER, THR, VAL
266	77	ALA, CYS, GLY, SER
267	78	GLU
268	79	ALA, ASN, ASP, CYS, GLY, SER, THR, VAL
269	80	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
270	81	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, SER, THR, VAL
271	82	ASP
272	83	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, MET, SER, THR, VAL
273	84	ALA, ASN, ASP, CYS, GLN, GLU, GLY, SER, THR
274	85	ALA, ARG, ASP, CYS, GLY, ILE, SER, THR, VAL
275	86	ALA, CYS, GLY, SER
276	87	GLY
277	88	ALA, GLY, SER
278	89	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, MET, SER, THR, VAL
279	90	ALA, GLY, SER
280	91	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, MET, PHE, PRO, SER, TRP, TYR
281	92	GLY
282	93	ALA, GLY, SER
283	94	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
284	95	CYS, HIS, ILE, LEU, MET, PHE, THR, TYR, VAL
285	96	ALA, GLY, SER
286	97	ALA, ASN, ASP, CYS, GLY, SER, THR, VAL
287	98	ALA, ASN, ASP, CYS, GLN, HIS, LEU, PHE, SER, TYR
288	99	HIS, PHE
289	100	ALA, GLY, SER
290	101	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
291	102	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
292	103	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
293	104	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PRO, SER, THR, VAL
294	105	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
295	106	GLY
296	107	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, VAL
297	108	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
298	109	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
299	110	ALA, GLY, SER
300	111	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
301	112	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, PHE, SER, THR, VAL
302	113	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, SER, THR, TRP, VAL
303	114	ALA, GLY, SER
304	115	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, SER, THR, VAL
305	116	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
306	117	ALA, ASN, ASP, SER
307	118	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
308	119	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
309	120	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
310	121	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
311	122	ALA, CYS, GLY, PRO, SER
312	123	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, THR, TRP, TYR
313	124	ALA, CYS, GLY, ILE, SER, THR, VAL
314	125	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, SER, THR, VAL
315	126	ALA, CYS, GLY, SER, THR
316	127	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, MET, SER, THR, VAL
317	128	ALA, ARG, CYS, GLY, SER, THR, VAL
318	129	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
319	130	ALA, ASN, ASP, CYS, GLN, GLY, HIS, MET, SER, THR
320	131	ALA, ARG, ASN, ASP, CYS, GLN, GLY, LYS, MET, SER
321	132	ALA, CYS, GLY, PRO, SER
322	133	ALA, ASP, CYS, GLN, GLU, GLY, LEU, SER
323	134	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, VAL,
324	135	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
325	136	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, TRP, TYR
326	137	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
327	138	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
328	139	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
329	140	ALA, ASP, CYS, GLY, SER
330	141	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
331	142	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
332	143	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
333	144	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, SER, THR, VAL
334	145	ALA, ARG, ASN, ASP, CYS, GLU, GLY, MET, SER, THR, VAL
335	146	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
336	147	ALA, ARG, CYS, GLN, GLU, GLY, MET, SER
337	148	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
338	149	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP,TYR, VAL,
339	150	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
340	151	ALA, ASN, ASP, GLY, SER
341	152	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, SER, THR, VAL
342	153	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
343	154	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
344	155	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
345	156	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TYR, VAL
346	157	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, THR
347	158	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LYS, MET, PRO, SER, THR, VAL
348	159	ALA, ASN, ASP, CYS, GLN, GLU, GLY, LEU, SER, THR, VAL
349	160	ALA, CYS, GLY, SER, THR
350	161	ALA, ASN, ASP, CYS, GLY, SER, THR
351	162	ALA, GLY, SER
352	163	GLY
353	164	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LYS, MET, SER, THR, VAL
354	165	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
355	166	GLY
356	167	ALA, GLY, SER
357	168	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, MET, SER, THR, VAL
358	169	ALA, GLY, SER
359	170	ASN, GLY
360	171	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
361	172	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
362	173	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
363	174	ASN, ASP, GLY, SER
364	175	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
365	176	ALA, ARG, ASN, ASP, CYS, GLY, HIS, MET, PHE, SER, THR, TRP, TYR
366	177	ALA, ARG, ASP, CYS, HIS, LYS, SER
367	178	ALA, ASP, CYS, GLY, SER, THR, VAL
368	179	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, THR, TRP, TYR
369	180	ALA, CYS, HIS, PHE, SER, TYR
370	181	ALA, ASP, CYS, GLY, PRO, SER
371	182	ALA, GLY, SER
372	183	ALA, CYS, GLY, SER
373	184	ALA, GLY, SER
374	185	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PRO, SER, THR, TRP, VAL
375	186	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
376	187	ALA, ASN, ASP, CYS, GLY, HIS, ILE, LEU, SER, THR, VAL
377	188	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, SER, THR, VAL
378	189	ALA, GLY, SER
379	190	ALA, ASP, CYS, GLY, SER, THR
380	191	GLY
381	192	GLY
382	193	ALA, CYS, GLY, SER, THR
383	194	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
384	195	ALA, ASN, ASP, CYS, GLN, GLU, GLY, LEU, SER, THR
385	196	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, SER, THR, TRP, VAL
386	197	ALA, CYS, GLY, MET, SER, THR
387	198	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
388	199	ASN, ASP, GLY, LYS, SER
389	200	GLY
390	201	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
391	202	ALA, ASN, ASP, CYS, GLN, GLY, ILE, MET, PRO, SER, THR, VAL
392	203	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
393	204	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
394	205	ALA, CYS, GLN, GLU, GLY, SER, THR
395	206	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LYS, MET, SER, THR, VAL
396	207	ALA, CYS, GLY, SER, THR, VAL
397	208	ALA, CYS, PHE, TRP, TYR
398	209	ARG, ASN, ASP, CYS, GLN, MET, SER
399	210	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LEU, LYS, MET, SER
400	211	GLY
401	212	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
402	213	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
403	214	GLY
404	215	GLY
405	216	ALA, GLY, SER
406	217	ALA, CYS, GLY, SER, THR
407	218	GLY
408	219	GLY
409	220	GLY
410	221	ALA, ASN, CYS, GLY, ILE, SER, THR, VAL
411	222	ALA, GLY, SER
412	223	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, SER, THR, VAL
413	224	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LYS, MET, PHE, SER, THR, TYR, VAL
414	225	ALA, ASN, CYS, GLN, GLU, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TYR, VAL
415	226	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
416	227	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, PRO, SER, THR, VAL
417	228	ALA, CYS, GLN, GLU, GLY, MET, PRO, SER, THR
418	229	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
419	230	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, PHE, SER, TRP, TYR
420	231	GLN, GLU
421	232	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
422	233	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
423	234	ALA, GLY, SER
424	235	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
425	236	ALA, CYS, GLY, PRO, SER, THR, VAL
426	237	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
427	238	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
428	239	ALA, ASN, ASP, CYS, GLN, GLU, GLY, SER, THR, VAL
429	240	ALA, ASN, ASP, CYS, GLY, SER
430	241	ALA, ASN, ASP, CYS, GLY, SER, THR
431	242	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
432	243	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
433	244	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
434	245	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, TYR, TRP, TYR, VAL
435	246	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
436	247	GLY
437	248	ALA, ARG, ASN, CYS, GLN, SER, THR
438	249	GLY
439	250	ALA, ARG, ASP, CYS, GLN, GLU, GLY, ILE, MET, SER, THR, VAL
440	251	ALA, GLY, PRO, SER
441	252	ASP
442	253	ALA, ASN, ASP, CYS, GLN, GLU, GLY, LEU, MET, SER THR
443	254	ALA, GLY, SER
444	255	ALA, GLY
445	256	ALA, ASN, ASP, CYS, GLY, SER
446	257	ALA, GLY, SER
447	258	ALA, ASN, ASP, CYS, GLY, SER, THR
448	259	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
449	260	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
450	261	ALA, ASN, ASP, CYS, GLY, HIS, SER, THR
451	262	GLY
452	263	ALA, ASN, CYS, GLN, HIS, ILE, LEU, PHE, SER, THR, TYR, VAL
453	264	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
454	265	ALA, ASN, ASP, CYS, GLY, SER, THR, VAL
455	266	ALA, ARG, ASN, ASP, CYS, GLU, GLY, HIS, ILE, MET, PHE, SER, THR, TRP, TYR, VAL
456	267	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, SER, THR, VAL
457	268	ALA, ASN, ASP, CYS, GLY, ILE, MET, SER, THR, TRP, VAL
458	269	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LYS, MET, SER
459	270	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL,
460	271	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TYR, VAL,
461	272	ALA, ASN, ASP, CYS, GLN, GLY, HIS, LYS, MET, SER, THR
462	273	ALA, ARG, ASN, ASP, CYS, GLN, GLY, HIS, ILE, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
463	274	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
464	275	GLY
465	276	GLY
466	277	ALA, ASN, ASP, CYS, GLY, SER, THR
467	278	SER
468	279	ALA, ASP, CYS, GLY, SER
469	280	ALA, ASN, ASP, CYS, GLY, SER, THR, VAL
470	281	ALA, GLY, SER
471	282	ALA, CYS, GLY, PRO, SER
472	283	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, MET, SER, THR, VAL
473	284	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
474	285	ALA, GLY, SER
475	286	ALA, GLY, SER
476	287	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, SER, THR, VAL
477	288	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, SER, THR, VAL
478	289	ALA, GLY, SER
479	290	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, SER, THR, TRP, TYR
480	291	ALA, ARG, ASN, ASP, CYS, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
481	292	ALA, ASN, ASP, CYS, GLN, GLU, GLY, MET, SER
482	293	ALA, GLN, GLU, HIS, LYS, THR
483	294	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, PHE, SER, TRP, TYR
484	295	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
485	296	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, TRP, TYR, VAL
486	297	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
487	298	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PRO, SER, THR, TRP, VAL
488	299	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, SER, THR, VAL
489	300	GLY
490	301	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
491	302	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, VAL
492	303	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PRO, SER, THR, VAL
493	304	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
494	305	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, YTR, VAL
495	306	ALA, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, MET, SER, THR
496	307	ALA, HIS, PHE, SER, THR, TYR
497	308	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
498	309	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LEU, MET, SER, THR
499	310	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR
500	311	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
501	312	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
502	313	ALA, ASN, ASP, CYS, GLY, ILE, MET, SER, THR, VAL
503	314	ALA, ASN, ASP, CYS, HIS, LEU, MET, PHE, SER, THR, TYR, VAL
504	315	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
505	316	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PRO, SER, THR, TRP, VAL
506	317	ALA, ASN, ASP, CYS, GLN, GLY, ILE, SER, THR, VAL
507	318	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
508	319	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
509	320	GLY
510	321	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, SER, THR, TRP, TYR
511	322	ALA, ARG, ASP, CYS, GLY, SER
512	323	ALA, ASN, ASP, CYS
513	324	ALA, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LYS, MET, SER, THR, VAL
514	325	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
515	326	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LYS, MET, SER
516	327	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP TYR, VAL
517	328	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
518	329	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
519	330	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
520	331	HIS, PHE, THR, TRP, TYR
521	332	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TYR, VAL
522	333	ALA, GLY, SER
523	334	CYS, GLY, HIS, LYS, MET, PHE, SER, TYR
524	335	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, PRO, SER, THR, TRP, TYR, VAL
525	336	GLY
526	337	HIS, PHE, TRP
527	338	ALA, ASN, ASP, CYS, SER
528	339	ALA, GLY, PRO, SER
529	340	ALA, ASP, CYS, GLY, SER, THR
530	341	ALA, ASN, CYS, GLY, SER, THR, VAL
531	342	GLY
532	343	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LEU, LYS, MET, SER
533	344	GLY
534	345	ALA, CYS, GLY, SER, THR
535	346	ALA, CYS, GLY, PRO, SER, THR
536	347	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, ILE, LEU, LYS, MET, PHE, SER, THR, TYR, VAL
537	348	GLY
538	349	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
539	350	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, LEU, LYS, MET, PHE, SER, THR, TRP, TYR
540	351	ALA, ASN, ASP, CYS, GLN, GLU, GLY, LEU, LYS, SER, THR, VAL
541	352	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, LEU, LYS, MET, SER, THR
542	353	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP, TYR, VAL
543	354	ALA, ARG, CYS, GLN, GLU, GLY, MET, SER, THR
544	355	ALA, ASN, ASP, CYS, GLN, GLU, GLY, LEU, MET, SER, THR
545	356	ALA, ARG, ASN, ASP, CYS, GLN, GLU, GLY, HIS, ILE, LEU, LYS, MET, PHE, SER, THR, TRP
546	357	Any residue
547	358	Any residue
548	359	Any residue
549	360	Any residue
550	361	Any residue
551	362	Any residue
552	363	Any residue
553	364	Any residue

In a further embodiment, the polypeptides of the invention comprise or consist of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2-42, 44-60 and 72-112, and 114-130 and 150-155, shown below. These polypeptides have increased activity relative to Kuma010, as shown in the examples that follow, or provide for improved production of the polypeptides. In one embodiment, the polypeptides comprise or consist of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2-42, 55-60 and 72-112, and 125-130 and 150-155; these polypeptides all show improved activity to Kuma010.

The N-terminal domain is in bold font, and changes relative to Kuma 011 are noted next to the polypeptide name. In all cases, the polypeptides described below may further comprise a histidine tag at the C-terminus. Any suitable histidine tag can be used; Any suitable histidine tag can be used; in one embodiment the tag is linked to a TEV protease cut sit (ENLYFQS) (SEQ NO: 149) to allow for its efficient removal with TEV protease after purification, for example, the tag may comprise or consist of the amino acid sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139). In another embodiment, a cleavable histidine tag may be incorporated at the C-terminus, comprising the amino acid sequence X_NPQ(L/Q)PX_NHHHHHH (SEQ ID NO: 131), wherein X_N is an linker of between 1-25 amino acid residues. In one non-limiting example, the cleavable histidine tag may comprise the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ ID NO: 132)

Kuma011-K262E
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAMAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI
HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 2 (unprocessed), SEQ ID NO: 72
(processed))

KumA011-V268A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEAELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 3 (unprocessed), SEQ ID NO: 73
(processed))

Kuma011-V268S
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGESELDIEVAGALAPGAKFAVYTAPDTTAGFLDAITTAI
HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETATVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 4 (unprocessed), SEQ ID NO: 74
(processed))

Kuma011-V268T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGETELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI
HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 5 (unprocessed), SEQ ID NO: 75
(processed))

Kuma011-E269L
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVLLDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 6 (unprocessed), SEQ ID NO: 76
(processed))

Kuma011-E269T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRIFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVTLDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 7 (unprocessed), SEQ ID NO: 77
(processed))

Kuma01-L270A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVEADIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 8 (unprocessed), SEQ ID NO: 78
(processed))

Kuma011-L270T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVETDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLNGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 9 (unprocessed), SEQ ID NO: 79
(processed))

Kuma011-L270V
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGIDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVEVDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 10 (unprocessed), SEQ ID NO: 80
(processed))

Kuma011-G319A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRREADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHERMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWAGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 11 (unprocessed), SEQ ID NO: 81
(processed))

Kuma011-S354A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDAGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 12 (unprocessed), SEQ ID NO: 82
(processed))

Kuma011-S354E
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDEGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 13 (unprocessed), SEQ ID NO: 83
(processed))

Kuma011-S354Q
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASTAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDQGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 14 (unprocessed), SEQ ID NO: 84
(processed))

Kuma011-S354R
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASTAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDRGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKVVGYLNPTLYQLPADVFEDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 15 (unprocessed), SEQ ID NO: 85
(processed))

Kuma011-S354Y
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDYGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 16 (unprocessed), SEQ ID NO: 86
(processed))

Kuma011-G358N
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTNGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 17 (unprocessed), SEQ ID NO: 87
(processed))

Kuma011-G358S
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRARFLDAAALGVTVLAAAGDSGSTSGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 18 (unprocessed), SEQ ID NO: 88
(processed))

Kuma011-G3580
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSNVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTQGE
QDGLYHVHFPAASPYVLACGGTRVLASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 19 (unprocessed), SEQ ID NO: 89
(processed))

Kuma011-G358T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTTGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVTFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 20 (unprocessed), SEQ ID NO: 90
(processed))

Kuma011-H368F
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVFFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLNGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTLLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 21 (unprocessed), SEQ ID NO: 91
(processed))

Kuma011-H368Q
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVYVLAAAGDSGSTGGE
QDGLYHVQFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 22 (unprocessed), SEQ ID NO: 92
(processed))

Kuma011-D3990
MSDMEKPWKEGFEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLAD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNQGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 23 (unprocessed), SEQ ID NO: 93
(processed))

Kuma011-D402S
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNQGPSGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 24 (unprocessed), SEQ ID NO: 94
(processed))

Kuma011-D4020
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGELDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNQGPQGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 25 (unprocessed), SEQ ID NO: 95
(processed))

Kuma011-T406S
MSDMEKPWKECEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGELDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNQGPQGGASGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 26 (unprocessed), SEQ ID NO: 96
(processed))

Kuma011-N424K
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAMAAMNRAFLDAAALGVTVLAAAGDSGSIGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNQGPQGGASGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 27 (unprocessed), SEQ ID NO: 97
(processed))

Kuma011-A449E
MSDMEKPWKEGEEARAVLQGEIARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAWFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYTAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPETGYEVVIDGEATVIGGTSAVAPLF
AALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDPC
TGLGSPIGVRLLQALLPSASOPQP (SEQ ID NO: 28 (unprocessed), SEQ ID NO: 98
(processed))

Kuma011-A449Q
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRREADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQNTASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYEAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADMEGYEVVIDGEATVIGGESAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 29 (unprocessed), SEQ ID NO: 99
(processed))

Kuma011-I456V
MSDMEKPWKECEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRREADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDCSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGNISRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVVDGEATVTGGTSAVAP
LFAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWD
PCTGLGSPIGMLLQALLPSASQPQP (SEQ ID NO: 30 (unprocessed), SEQ ID NO: 100
(processed))

Kuma011-T461R
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASTAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETATWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEARVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYOAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 31 (unprocessed), SEQ ID NO: 101
(processed))

Kuma011-I463A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASTAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAWFASLQVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTYLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVAGGISAVAPL
FAALVARINQKLGKVGYLNPTLYQUADVFFIDITEGNNIMANRAQPIQAGPGWDP
CRTLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 32 (unprocessed), SEQ ID NO: 102
(processed))

Kuma011-I463L
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTITASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAVYTASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGYPDLAGNADPATGYEVVIDGEATVLGGTSAVAPL
FAALVARINQKLGKVGYLNPTLYQLPADVHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 33 (unprocessed), SEQ ID NO: 103
(processed))

Kuma011-I463M
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAMAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGCIAIIELGGGYDEASLAVYTASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVNIGGTSAVAP
LFAALVARINQKLGKAVGYLNPTLYQLPADVFFIDITEGNNDIANRAQIYQAGPGWD
PCTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 34 (unprocessed), SEQ ID NO: 104
(processed))

Kuma011-I463Q
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAMAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVNTAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVQGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 35 (unprocessed), SEQ ID NO: 105
(processed))

Kuma011-I463R
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVRGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 36 (unprocessed), SEQ ID NO: 106
(processed))

Kuma011-I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVNTAPDTIAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLNGNADPATGYEVVIDGEATVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 37 (unprocessed), SEQ ID NO: 107
(processed))

Kuma011-I463V
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVVGGtSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 38 (unprocessed), SEQ ID NO: 108
(processed))

Kuma023: G368S; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIENTAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTSGE
QDGLYHVFHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 39 (unprocessed), SEQ ID NO: 109
(processed))

Kuma 020 as referenced in the examples is the Kuma023 polypeptide that includes the following C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139).

Kuma021: G368S: D399Q, A449Q, I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQ

RAGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHG

LALDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVP

ASIAPMIEAVLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLG

VPAPQVVSVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFA

PDTTAGFLDAITTAIHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLD

AAALGVTVLAAAGDSGSTSGEQDGLYHVHFPAASPYVLACGGTRLVASGG

RIAQETVWNQGPDGGATGGGVSRIFPLPAWQEHANVPPSANPGASSGRGV

PDLAGNADPQTGYEVVIDGEATVTGGTSAVAPLFAALVARINQKLGKAVG

YLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDPCTGLGSPIGVR

LLQALLPSASQPQP (SEQ ID NO: 154 (unprocessed), SEQ

ID NO: 155 (processed))

Kuma031: K262E; E269T; S354Q; G358S, D399Q; A449Q;
I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQ

RAGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHG

LALDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVP

ASIAPMIEAVLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLG

VPAPQVVSVSVDGASNQPTGDPEGPDGEVTLDIEVAGALAPGAKFAVYFA

PDTTAGFLDAITTAIHDPITKPSVVSISWSGPEDSWTSAAIAAMNRAFLD

AAALGVTVLAAAGDQGSTSGEQDGLYHVHFPAASPYVLACGGTRLVASGG

RIAQETVWNQGPDGGATGGGVSRIFPLPAWQEHANVPPSANPGASSGRGV

PDLAGNADPQTGYEVVIDGEATVTGGTSAVAPLFAALVARINQKLGKAVG

YLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGNVDPCTGLGSPIGV

RLLQALLPSASQPQP (SEQ ID NO: 40 (unprocessed), SEQ

ID NO: 110 (processed))

Kuma 030 as referenced in the examples is the Kuma031 polypeptide that includes the following C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139).

Kuma041: S319A; H368F; D399q; A449q; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRR

QRAGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADA

HGLALDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEV

TVPASIAPMIEAVLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASL

GVPAPQVVSVSVDGASNQPTGDPKGPDGEVTVDIEVAGALAPGAKFAVY

FAPDTTAGFLDAITTAIHDPTLKPSVVSISWAGPEDSWTSAAIAAMNRA

FLDAAALGVTVLAAAGDQGSTSGEQDGLYHVHFPAASPYVLACGGTRLV

ASGGRIAQETVWNQGPDGGATGGGVSRIFPLPAWQEHANVPPSANPGAS

SGRGVPDLAGNADPQTGYEVVIDGEATVIGGTSAVAPLFAALVARINQK

LGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDPCTGL

GSPIGVRLLQALLPSASQPQP (SEQ ID NO: 41

(unprocessed), SEQ ID NO: 111 (processed))

Kuma 040 as referenced in the examples is the Kuma041 polypeptide that includes the following C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139).

Kuma051: K262E: E269T; L270V; S354Q, G358S; D399Q;
A449Q
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLA

LDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASI

APMIEAVLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGV

PAPQVVSVSVDGASNQPTGDPEGPDGEVTVDIEVAGALAPGAKFAVYFAPD

TTAGFLDAITTAIHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAA

LGVTVLAAAGDQGSTSGEQDGLYHVHFPAASPYVLACGGTRLVASGGRIAQ

ETVWNQGPDGGATGGGVSRIFPLPAWQEHANVPPSANPGASSGRGVPDLAG

NADPQTGYEVVIDGEATVIGGTSAVAPLFAALVARINQKLGKAVGYLNPTL

YQLPADVFHDITEGNNDIANRAQIYQAGPGWDPCTGLGSPIGVRLLQALLP

SASQPQP (SEQ ID NO: 42 (unprocessed), SEQ ID

NO: 112 (processed))

Kuma 050 as referenced in the examples is the Kuma051 polypeptide that includes the following C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139).

Kuma022: P171R; H172R; G368S; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARRRFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTSGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETATWNDGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 55 (unprocessed), SEQ ID NO: 125
(processed))

Kuma032: P171R; H172R; K262E; E269T; S354Q; G358S; D399Q; A449Q; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARRRFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPEGPDGEVTLDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI
HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDQGSTSGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETATWNQGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPQTGYEVVIDGEATVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 56 (unprocessed), SEQ ID NO: 126
(processed))

Kurna042: P171R; H172R; S319A; H368F; D399Q; A449Q; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA
VLGLDTRPVARRRFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAWFASLGVPAPQVV
SVSVDGASNQPTGDPKGPDGEVTLDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWAGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE
QDGLYHVFFPAASPYVLACGGTRLVASGGRIAQETATWNQGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPQTGYEVVIDGEATVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNIMANRAQPIQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 57 (unprocessed), SEQ ID NO: 127
(processed))

Kuma052: P171R; H172R; K262E; E269T; L270V; S354Q; G358S; D399Q: A449Q
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHDCSYRSYLGEVTITASIAPMIEA
VLGLDTRPVARRRFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPEGPDGEVTVDIIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA
IHDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDQGSTSGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNQGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPQTGYEVVIDGEATVIGGISAVAPL
FAALVARINQKLGICVVGYLNPTLYQLPADVFFIDITEGNNDIANRAQPIQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 58 (unprocessed), SEQ ID NO: 128
(processed))

Kuma061: K262E; E269T: S354Q; G358S; D399Q; A449Q; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR
AGELAAHVERQAMAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD
RANVAAGTAVLSGPDDAINRAFGVELRHFDHDGSYRSYLGEVTITASIAPMIEA
VLGLDTRPVARPHFRMQRRAEGGFEARSQA
AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV
SVSVDGASNQPTGDPEGPDGEVTLDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI
HDPTLKPSVVSISWSMPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDQGSTSGE
QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQEFVWNQGPDGGATGGGVSRIFPL
PAWQEHANVPPSANPGASSGRGVPDLAGNADPQTGYEVVIDGEATVTGGTSAVAPL
FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP
CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 150 (unprocessed), SEQ ID NO: 151
(processed))

Kuma 060 as referenced in the examples is the Kuma061 polypeptide that includes the following C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139).

Kuma062: P171R; H172R; K262E; E269T; S354Q; G358S;
D399Q; A449Q; I463T
MSDMEKPWKEGFEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQ

RAGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHG

LALDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVP

ASIAPMIEAVLGLDTRPVARRRFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLG

VPAPQVVSVSVDGASNQPTGDPEGPDGEVTLDIEVAGALAPGAKFAVYFA

PDTTAGFLDAITTAIHDPTLKPSVVSISWSMPEDSWTSAAIAAMNRAFLD

AAALGVTVLAAAGDQGSTSGEQDGLYHVHFPAASPYVLACGGTRLVASGG

RIAQETVWNQGPDGGATGGGVSRIFPLPAWQEHANVPPSANPGASSGRGV

PDLAGNADPQTGYEVVIDGEATVTGGTSAVAPLFAALVARINQKLGKAVG

YLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDPCTGLGSPIGVR

LLQALLPSASQPOP (SEQ ID NO: 59 (unprocessed),

SEQ ID NO: 129 (processed))

Kuma071: S319A; H368F; D399Q; A449Q; I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQ

RAGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHG

LALDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVP

ASIAPMIEAVLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGCIAIIELGGGYDEASLAQYFASLGV

PAPQVVSVSVDGASNQPTGDPKGPDGEVTLDIEVAGALAPGAKFAVYFAP

DTTAGFLDAITTAIHDPTLKPSVVSISWAMPEDSWTSAAIAAMNRAFLDA

AALGVTVLAAAGDSGSTGGEQDGLYHVFFPAASPYVLACGGTRLVASGGR

IAQETVWNQGPDGGATGGGVSRIFPLPAWQEHANVPPSANPGASSGRGVP

DLAGNADPQTGYEVVIDGEATVTGGTSAVAPLFAALVARINQKLGKAVGY

LNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDPCTGLGSPIGVRL

LQALLPSASQPQP (SEQ ID NO: 152(unprocessed), SEQ ID

NO: 153 (processed))

Kuma 070 as referenced in the examples is the Kuma071 polypeptide that includes the following C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID M): 139).

Kuma072: P171R; H172R; S319A; H368F; D399Q; A449Q;
I463T
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQ

RAGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHG

LALDRANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTIT

ASIAPMIEAVLGLDTRPVARRRFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLG

VPAPQVVSVSVDGASNQPTGDPKGPDGEVTLDIEVAGALAPGAKFAVYFA

PDTTAGFLDAITTAHIDPTLKPSVVSISWAMPEDSWTSAAIAAMNRAFLD

AAALGVTVLAAAGDSGSTGGEQDGLYHVFFPAASPYVLACGGTRLVASGG

RIAQETVWNQGPDGGATGGGNISRIFPLPAWQEHANVPPSANPGASSGRG

VPDLAGNADPQTGYEVVIDGEATVTGGTSAVAPLFAALVARINQKLGKAV

GYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDPCTGLGSPIGV

RLLQALLPSASQPQP (SEQ ID NO: 60 (unprocessed), SEQ
ID NO: 130(processed))

As described in Table 5, the changes made to Kuma010/011 have significant effect on the catalytic activity of the design proteins. Table 5 lists the effectiveness of individual mutations in catalyzing the degradation of various gliadin peptide sequences. The examples provide further data regarding specific individual and combination mutants.

TABLE 5
				% Improvement	% Improvement
Position	Position	Kuma010	A.A. relative	on PFPQPQLPY	on PFPQPQQPF
(Full Length)	(Truncated)	A.A.	to Kuma010/011	(SEQ ID NO: 67)	(SEQ ID NO: 68)
221	32	E	D, N, Q, H	105%	ND
262	73	K	E	109%	110%
268	79	V	A	107%	89%
268	79	V	S	104%	83%
268	79	V	T	127%	105%
269	80	E	L	113%	84%
269	80	E	T	263%	191%
270	81	L	A	203%	92%
270	81	L	T	307%	29%
270	81	L	V	474%	61%
319	130	S	A	154%	184%
354	165	S	A	152%	140%
354	165	S	E	124%	120%
354	165	S	Q	145%	141%
354	165	S	R	109%	82%
354	165	S	Y	46%	105%
358	169	G	N	120%	99%
358	169	G	S	331%	224%
358	169	G	Q	147%	149%
358	169	G	T	283%	128%
368	179	H	F	334%	104%
368	179	H	Q	199%	195%
399	210	D	Q	149%	208%
402	213	D	S	94%	108%
402	213	D	Q	164%	111%
406	217	T	S	84%	101%
424	235	N	K	285%	ND
449	260	A	E	149%	208%
449	260	A	N	119%	118%
461	272	T	R	120%	86%
463	274	I	A	51%	234%
463	274	I	L	124%	22%
463	274	I	M	123%	53%
463	274	I	Q	129%	69%
463	274	I	R	29%	110%
463	274	I	T	130%	239%
463	274	I	V	256%	141%

Improved Production Mutations

Mutations that improve production may provide improvements in one of three categories: 1. Altering purification method; 2. increase in yield; and 3. decreasing the probability that enzymatic self-processing would occur during purification, thereby simplifying analysis. Addition of a His tag that is removable by the proteolytic activity of the polypeptides disclosed herein frills into category 1; R105H mutant appears to improve yield by ˜2-fold, placing this mutation into category 2; and mutations in positions 171-174 place these mutants into category 3.

Kuma010 with Kuma010-Cleavable His Tag
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAMAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPMAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGCIAIIELGGGYDEASLAVYTASLGVPAPQVV

SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA

IHDPTLKPSVVSISWSGPEDSWTSAAIAAIMNRAFLDAAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQPGSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ

ID NO: 43 (unprocessed), SEQ ID NO: 113 (processed))

Kuma011-R105H
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGISAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQTYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 44 (unprocessed), SEQ

ID NO: 114 (processed))

Kuma01-P171A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARAHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVTAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVTGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQTYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 45 (unprocessed), SEQ

ID NO: 115 (processed))

Kuma011-P171R
MSDMEKPWKEGFEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARRHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGNIPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSIGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 46 (unprocessed), SEQ

ID NO: 116 (processed))

Kuma01-P171S
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARSHFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 47 (unprocessed), SEQ

ID NO: 117 (processed))

Kuma011-H172A
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPAFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLADAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 48 (unprocessed), SEQ ID

NO: 118 (processed))

Kuma011-H172R
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPRFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVTAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 49 (unprocessed), SEQ ID

NO: 119 (processed))

Kuma011-H172S
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPSFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPIGDPEGPDGEVELDIEVAGALAPGAKFAVPFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSIGGE

QDGLYHVHFPAASPYVLACGGTRLVSGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 50 (unprocessed), SEQ ID

NO: 120 (processed))

Kuma011-F173R
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAMAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPHSRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTFAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 51 (unprocessed), SEQ ID

NO: 121 (processed))

Kuma011-F173S
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPHSRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVTAAAGDSGSTGGE

QDGLYHVHPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVRARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQFYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 52 (unprocessed), SEQ ID

NO: 122 (processed))

Kuma011-R174S
MSDMEKPWKECEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARPHFSMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPEGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTAI

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 53 (unprocessed), SEQ ID

NO: 123 (processed))

Kuma012: P171R; H172R
MSDMEKPWKEGEEARAVLQGHARAQAPQAVDKGPVAGDERMAVTVVLRRQR

AGELAAHVERQAAIAPHAREHLKREAFAASHGASLDDFAELRRFADAHGLALD

RANVAAGTAVLSGPDDAINRAFGVELRHFDHPDGSYRSYLGEVTVPASIAPMIEA

VLGLDTRPVARRRFRMQRRAEGGFEARSQA

AAPTAYTPLDVAQAYQFPEGLDGQGQCIAIIELGGGYDEASLAQYFASLGVPAPQVV

SVSVDGASNQPTGDPKGPDGEVELDIEVAGALAPGAKFAVYFAPDTTAGFLDAITTA

HDPTLKPSVVSISWSGPEDSWTSAAIAAMNRAFLDAAALGVTVLAAAGDSGSTGGE

QDGLYHVHFPAASPYVLACGGTRLVASGGRIAQETVWNDGPDGGATGGGVSRIFPL

PAWQEHANVPPSANPGASSGRGVPDLAGNADPATGYEVVIDGEATVIGGTSAVAPL

FAALVARINQKLGKAVGYLNPTLYQLPADVRFHDITEGNNDIANRAQIYQAGPGWDP

CTGLGSPIGVRLLQALLPSASQPQP (SEQ ID NO: 54 (unprocessed), SEQ

ID NO: 124 (processed))

As used throughout the present application, the term “polypeptide” is used in its broadest sense to refer to a sequence of subunit amino acids, whether naturally occurring or of synthetic origin. The polypeptides of the invention may comprise L-amino acids. D-amino acids (which are resistant to L-amino acid-specific proteases in vivo), or a combination of D- and L-amino acids. The polypeptides described herein may be chemically synthesized or recombinantly expressed. The polypeptides may be linked to other compounds to promote an increased half-life in vivo, such as by PEGylation, HESylation, PASylation, or glycosylation. Such linkage can be covalent or non-covalent as is understood by those of skill in the art. The polypeptides may be linked to any other suitable linkers, including but not limited to any linkers that can be used for purification or detection (such as FLAG or His tags).

In another aspect, the present invention provides isolated nucleic acids encoding the polypeptide of any aspect or embodiment of the invention. The isolated nucleic acid sequence may comprise RNA or DNA. As used herein, “isolated nucleic acids” are those that have been removed from their normal surrounding nucleic acid sequences in the genome or in cDNA sequences. Such isolated nucleic acid sequences may comprise additional sequences useful for promoting expression and/or purification of the encoded protein, including but not limited to polyA sequences, modified Kozak sequences, and sequences encoding epitope tags, export signals, and secretory signals, nuclear localization signals, and plasma membrane localization signals. It will be apparent to those of skill in the art, based on the teachings herein, what nucleic acid sequences will encode the polypeptides of the invention.

In a further aspect, the present invention provides nucleic acid expression vectors comprising the isolated nucleic acid of any embodiment of the invention operatively linked to a suitable control sequence. “Recombinant expression vector” includes vectors that operatively link a nucleic acid coding region or gene to any control sequences capable of effecting expression of the gene product. “Control sequences” operably linked to the nucleic acid sequences of the invention are nucleic acid sequences capable of effecting the expression of the nucleic acid molecules. The control sequences need not be contiguous with the nucleic acid sequences, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the nucleic acid sequences and the promoter sequence can still be considered “operably linked” to the coding sequence. Other such control sequences include, but are not limited to, polyadenylation signals, termination signals, and ribosome binding sites. Such expression vectors can be of any type known in the art, including but not limited plasmid and viral-based expression vectors. The control sequence used to drive expression of the disclosed nucleic acid sequences in a mammalian system may be constitutive (driven by any of a variety of promoters, including but not limited to, CMV, SV40, RSV, actin, EF) or inducible (driven by any of a number of inducible promoters including, but not limited to, tetracycline, ecdysone, steroid-responsive). The construction of expression vectors for use in transfecting prokaryotic cells is also well known in the art, and thus can be accomplished via standard techniques. (See, for example, Sambrook, Fritsch, and Maniatis, in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989; Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, Tex.). The expression vector must be replicable in the host organisms either as an episome or by integration into host chromosomal DNA In a preferred embodiment, the expression vector comprises a plasmid. However, the invention is intended to include other expression vectors that serve equivalent functions, such as viral vectors.

In another aspect, the present invention provides recombinant host cells comprising the nucleic acid expression vectors of the invention. The host cells can be either prokaryotic or eukaryotic. The cells can be transiently or stably transfected or transduced. Such transfection and transduction of expression vectors into prokaryotic and eukaryotic cells can be accomplished via any technique known in the art, including; but not limited to standard bacterial transformations, calcium phosphate co-precipitation, electroporation, or liposome mediated-, DEAE dextran mediated-, polycationic mediated-, or viral mediated transfection. (See, for example, Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press; Culture of Animal Cells: A Manual of Basic Technique, 2^nd Ed. (R. I. Freshney, 1987. Liss, Inc. New York, N.Y.). A method of producing a polypeptide according to the invention is an additional part of the invention. The method comprises the steps of (a) culturing a host according to this aspect of the invention under conditions conducive to the expression of the polypeptide, and (b) optionally, recovering the expressed polypeptide. The expressed polypeptide can be recovered from the cell free extract, cell pellet, or recovered from the culture medium. Methods to purify recombinantly expressed polypeptides are well known to the man skilled in the art.

In a further aspect, the present invention provides pharmaceutical compositions, comprising the polypeptide, nucleic acid, nucleic acid expression vector, and/or the recombinant host cell of any aspect or embodiment of the invention, and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention can be used, for example, in the methods of the invention described below. The pharmaceutical composition may comprise in addition to the polypeptides, nucleic acids, etc. of the invention (a) a lyoprotectant; (b) a surfactant; (c) a bulking agent; (d) a tonicity adjusting agent; (e) a stabilizer; (f) a preservative and/or (g) a buffer.

In some embodiments, the buffer in the pharmaceutical composition is a Tris buffer, a histidine buffer, a phosphate buffer, a citrate buffer or an acetate buffer. The pharmaceutical composition may also include a lyoprotectant, e.g. sucrose, sorbitol or trehalose. In certain embodiments, the pharmaceutical composition includes a preservative e.g. benzalkonium chloride, benzethonium, chlorohexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutinol, o-cresol, p-cresol, chlorocresol, phenylinereuric nitrate, thimerosal, benzoic acid, and various mixtures thereof. In other embodiments, the pharmaceutical composition includes a bulking agent, like glycine. In yet other embodiments, the pharmaceutical composition includes a surfactant e.g., polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80 polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan manopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleaste, or a combination thereof. The pharmaceutical composition may also include a tonicity adjusting agent, e.g., a compound that renders the formulation substantially isotonic or isoosmotic with human blood. Exemplary tonicity adjusting agents include sucrose, sorbitol, methionine, mannitol, dextrose, inositol, sodium chloride, arginine and arginine hydrochloride. In other embodiments, the pharmaceutical composition additionally includes a stabilizer, e.g., a molecule which, when combined with a protein of interest substantially prevents or reduces chemical and/or physical instability of the protein of interest in lyophilized or liquid form. Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride.

The polypeptides, nucleic acids, etc. of the invention may be the sole active agent in the pharmaceutical composition, or the composition may further comprise one or more other active agents suitable for an intended use.

The pharmaceutical compositions described herein generally comprise a combination of a compound described herein and a pharmaceutically acceptable carrier, diluent, or excipient. Such compositions are substantially free of non-pharmaceutically acceptable components, i.e., contain amounts of non-pharmaceutically acceptable components lower than permitted by US regulatory requirements at the time of filing this application. In some embodiments of this aspect, if the compound is dissolved or suspended in water, the composition further optionally comprises an additional pharmaceutically acceptable carrier, diluent, or excipient. In other embodiments, the pharmaceutical compositions described herein are solid pharmaceutical compositions (e.g., tablet, capsules, etc).

The compositions described herein could also be provided as a dietary supplement as described by the US regulatory agencies.

These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by any suitable route. In a preferred embodiment, the pharmaceutical compositions and formulations are designed for oral administration. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

The pharmaceutical compositions can be in any suitable form, including but not limited to tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

In another aspect, the present invention provides methods for treating celiac sprue or non-celiac gluten sensitivity (NCGS), comprising administering to an individual with celiac sprue or NCGS an amount effective to treat the celiac sprue or NCGS of one or more polypeptides selected from the group consisting of the polypeptides of the of the invention, or using one or more of these polypeptides to process food for consumption by individuals with celiac sprue or NCGS

The inventors of the present invention have discovered that the polypeptides of the invention are capable of degrading proline (P)- and glutamine (Q)-rich components of gluten known as ‘gliadins’ believed responsible for the bulk of the immune response in most celiac sprue patients. The polypeptides of the present invention show superior activity in degrading peptides having a PQLP (SEQ ID NO: 65) or PQQP (SEQ ID NO: 66) motif (such as PFPQPQLPY (SEQ ID NO: 67) and/or PFPQPQQPF (SEQ ID NO: 68)), which are substrates representative of gliadin) at pH 4 compared to Kuma010/011 and other polypeptides disclosed as useful for treating celiac sprue (WO2015/023728). Thus, the polypeptides of the invention constitute significantly improved therapeutics for treating celiac sprue and NCGS.

Celiac sprue (also known as celiac disease or gluten intolerance) is a highly prevalent disease in which dietary proteins found in wheat, barley, and rye products known as ‘glutens’ evoke an immune response in the small intestine of genetically predisposed individuals. The resulting inflammation can lead to the degradation of the villi of the small intestine, impeding the absorption of nutrients. Symptoms can appear in early childhood or later in life, and range widely in severity, from diarrhea, fatigue, weight loss, abdominal pain, bloating, excessive gas, indigestion, constipation, abdominal distension, nausea/vomiting, anemia, bruising easily, depression, anxiety, growth delay in children, hair loss, dermatitis, missed menstrual periods, mouth ulcers, muscle cramps, joint pain, nosebleeds, seizures, tingling or numbness in hands or feet, delayed puberty, defects in tooth enamel, and neurological symptoms such as ataxia or paresthesia. There are currently no effective therapies for this lifelong disease except the total elimination of glutens from the diet. Although celiac sprue remains largely underdiagnosed, its' prevalence in the US and Europe is estimated at 0.5-1.0% of the population. In addition to celiac sprue, a significant fraction of the population is thought to suffer from the condition of non-celiac gluten sensitivity (NCGS), which is caused by the ingestion of gluten but is mechanistically distinct from celiac disease, though the symptoms are frequently indistinguishable from those of celiac sprue.

As used herein, “treating celiac sprue or NCGS” means accomplishing one or more of the following: (a) reducing the severity of celiac sprue or NCGS; (b) limiting or preventing development of symptoms characteristic of celiac sprue or NCGS; (c) inhibiting worsening of symptoms characteristic of celiac sprue or NCGS; (d) limiting or preventing, recurrence of celiac sprue or NCGS in patients that have previously had the disorder; (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for celiac sprue or NCGS; and (f) limiting development of celiac sprue or NCGS in a subject at risk of developing celiac sprue or NCGS, or not yet showing the clinical effects of celiac sprue or NCGS.

The individual to be treated according to the methods of the invention may be any individual suffering from celiac sprue or NCGS, including human subjects. The individual may be one already suffering from symptoms or one who is asymptomatic.

As used herein, an “amount effective” refers to an amount of the polypeptide that is effective for treating celiac sprue. The polypeptides are typically formulated as a pharmaceutical composition, such as those disclosed above, and can be administered via any suitable route, including orally, parentally, by inhalation spray, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. In a preferred embodiment, the pharmaceutical compositions and formulations are orally administered, such as by tablets, pills, lozenges, elixirs, suspensions, emulsions, solutions, or syrups.

Dosage regimens can be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). A suitable dosage range may, for instance, be 0.1 ug/kg-100 mg/kg body weight; alternatively, it may be 0.5 ug/kg to 50 mg/kg; 1 ug-kg to 25 mg/kg, or 5 ug/kg to 10 mg/kg body weight. The polypeptides can be delivered in a single bolus, or may be administered more than once (e.g., 2, 3, 4, 5, or more times) as determined by an attending physician.

EXAMPLE 1

Gliadin is highly enriched in proline (P) and glutamine (Q), which renders it recalcitrant to degradation by human digestive enzymes. PQ-rich peptide fragments derived from partial digestion of gliadin are deamidated in the intestinal lumen, thereby allowing binding to HLA-DQ2 or DQ8, and stimulation of a Th1 inflammatory response in people with CD³. The gliadin endopeptidase KUMAMAX™ (hereafter referred to as Kuma011, or Kuma 010 if referring to Kuma011 including the C-terminal histidine tag: GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139)), which demonstrates stability and functionality in gastric conditions, was previously engineered to break down peptides containing the PQ dipeptide motif¹. Based on the crystal structure of Kuma010 (PDB ID 4NE7), we redesigned the active site of Kuma010 selecting for mutations to increase activity against immunogenic gliadin peptides. Designed mutants were then screened for increased activity against the highly immunogenic 33mer (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 69)) and 26mer (FLQPQQPFPQQPQQPYPQQPQQPFPQ (SEQ ID NO: 70)) gliadin peptides^6,7. These peptides harbor either the PQL or PQQ tripeptide motif, representative of all gliadin T cell epitopes shown to be toxic for the vast majority of celiac patients⁸. In this manner, the variant Kuma030 was built. Kuma030 is 44-fold more active against peptides containing PQQ, and 11-fold more active against peptides containing PQL, than Kuma010.

Based on the molecular modeling, the putative S1′ peptide binding interface of Kuma010 consists of entirely hydrophobic residues, and should therefore prefer hydrophobic residues such as leucine, and not polar residues such as glutamine, at P1′. The S1′ binding pocket of Kuma030 introduces an isoleucine to threonine mutation (I463T), which is predicted to provide a hydrogen bond with a P1′ glutamine, enabling this enzyme to accommodate both leucine and glutamine in the S1′ subsite and thereby target both PQL, and PQQ tripeptides. Kuma030 also incorporates six additional mutations (K262E, E269T, S354Q, G358S, D399Q, A449Q) that provide enhanced catalytic efficiency on the 26mer and 33mer peptides. G358S is predicted to stabilize the loop containing an engineered histidine introduced in Kuma010 which is predicted to hydrogen bond to the P1 glutamine residue. The remaining mutations are predicted to stabilize the protein structure as modeled.

While dozens of PQ-rich epitopes have been linked to CD, several peptides derived from gliadin (wheat), hordein (barley), and secalin (rye) have been shown to account for the vast majority of the immune response in CD and have thus been classified as immunodominant⁸. In wheat, these include the peptides W02-E07 (LQPFPQPQLPYPQPQ (SEQ ID NO: 1. W03-E07 (QPFPQPQQPFPWQP (SEQ ID NO: 134)), and the 33mer peptide, which contains the W02-E07 sequence^6,9. These peptides harbor several epitopes shown to be highly immunogenic^9-11. To evaluate the ability of Kuma030 to destroy these epitopes throughout gluten, purified whole gluten was incubated with Kuma030 under simulated gastric conditions (pH 4.0 at 37° C. with 0.6 mg mL⁻¹ pepsin)¹². The gluten fraction remaining after degradation was quantified using ELISA assays based on either the R5 or G12 antibodies recognizing the amino acid motifs QQPFP (SEQ II) NO: 135) and QPQLPY (SEQ ID NO: 136), respectively, which encompass all of the immunodominant epitopes in the above peptides^13-14. To compare the activity of Kuma030 to that of published glutenases, we also examined the glutenases EPB2 and SCPEP, which are currently being pioneered at a 1:1 ratio as a combination enzyme therapeutic for CD¹⁵. The EPB2 and SCPEP enzymes generated in this work were verified to have activities consistent with a of published values^16,17. Upon incubation with gluten, we observed a dose-dependent reduction in the QQPFP (SEQ ID NO: 135) or QPQLPY (SEQ ID NO: 136) load using; either Kuma030, Kuma010, or a 1:1 combination of EPB2 and SCPEP (FIG. 1A). At a 1:25 w:w ratio of enzyme:gluten, EPB2 and SCPEP broke down 84.8% of the gluten present, consistent with previously published reports of this enzyme combination^18,19. Kuma030 was highly effective at eliminating these peptide epitopes throughout gluten, with a 1:400 w:w ratio of enzyme:gluten being sufficient to reduce the immunogenic gluten present by over 99.5% at 60 minutes, as quantified by both methods used (FIG. 1A). Kuma030-dependent reduction in immunogenic gluten load is rapid, with >98% degradation achieved by 5 minutes at a w:w ratio of 1:25 (FIG. 1B). Mass spectroscopy of the Kuma030 cleavage products revealed that Kuma030 cleaved each peptide after the PQ dipeptide motif in the immunodominant epitopes from wheat (33mer, W02-E07, and W03-E07), and also those from barley B08-E2E7 (PQQPIPQQPQPYPQQ (SEQ NO: 61)) and rye R11-E2E7 (QPFPQQPEQIIPQQP)⁹ (SEQ ID NO: 62) (FIG. 1C). While these intact peptides are highly immunostimulatory, the peptide breakdown products are not predicted to stimulate the immune system, since Kuma030 action results in elimination of the core 9mer epitope thought to trigger the immune response²⁰. The ability of Kuma030 to cleave these peptides containing either a PQL or a PQQ tripeptide motif, and to reduce the gliadin load as measured by both G12 and R5 antibodies, are consistent with the hypothesis that Kuma030 can bind and cleave peptides with either a leucine or a glutamine in the S1′ binding pocket.

The ability of Kuma030 to efficiently degrade immunogenic gliadin epitopes suggests that incubation of gliadin with Kuma030 might reduce its capacity to stimulate a T-cell mediated immune response. T cell assays utilizing cells derived from the intestinal biopsies of celiac patients represent the gold standard for this evaluation. To directly evaluate the hypothesis that incubation with Kuma030 would decrease or eliminate the immunostimulatory capacity of gliadin, we performed T cell assays in which cells were exposed to Kuma030-treated gliadin and the resulting T cell reaction was assessed. The highly gliadin-reactive intestinal CD4⁺ T cell lines used in this study were previously generated from intestinal mucosa and have been shown to react to a diversity of epitopes across different gliadin families²¹. Kuma030 and pepsin were incubated with purified wheat gliadin in laboratory-simulated gastric conditions for 60 minutes. In order to mimic transit into the intestinal compartment, the pH levels of the samples were then increased, and the samples were treated with chymotrypsin and deamidated with TG2 to unmask the immunogenic epitopes. The resulting gliadin samples were presented to T cell lines, and stimulation was assessed by measuring IFN-γ production (FIG. 2A-E) and T cell proliferation (FIG. 3A-D). Exposure of T cell lines to pepsin-treated gliadin resulted in stimulation of production of IFN-γ, and co-treatment of gliadin with pepsin and Kuma030 reduced this response, eliminating it at higher concentrations. The decreases observed in IFN-γ production were not due to Kuma030 toxicity. Importantly, Kuma030 eliminated the T cell response to gliadin in every T cell line tested regardless of T cell epitope specificity, indicating that Kuma030 is effective against all epitopes recognized by the T cell lines used in this assay. Since these epitopes span the three major gliadin families: α-, ω-, and γ-gliadin, this suggests that Kuma030 is capable of degrading immunogenic epitopes within all relevant regions of gliadin.

The experiments above demonstrate the ability of Kuma030 to degrade immunogenic gliadin epitopes in the context of purified whole gluten or gliadin. However, to assess practical application, it is important to evaluate Kuma030 effectiveness in physiologically relevant food and beverage matrices. To assess the activity of Kuma030 in gastric digestion scenarios, we tested the ability of Kuma030 to break down gluten in an acidified bread slurry and in a wheat beer. Whole-wheat bread was mashed in artificial saliva to simulate mastication at a bread concentration representative of that in the stomach after ingestion of one slice of bread. The mixture was then acidified by the addition of HCl and pepsin, and glutenases at various concentrations were added. The amount of gluten remaining was then quantified after 30 minutes of digestion, which represents the average lag time of food in the stomach before the commencement of ingesta release into the duodenum through the pyloric opening²². At the highest concentration of glutenase tested (1000 μg mL⁻¹), treatment with EPB2 and SCPEP resulted in 84.4% gluten degradation (FIG. 4A). This is comparable to published results from a Phase I study showing that EPB2 and SCPEP eliminate 70-79% of gluten in a test meal at a 1:10 enzyme:gluten ratio in the human stomach after a 30 minute incubation time²³. At a concentration of 62.5 μg, mL⁻¹ (a 1:160 w:w ratio), Kuma030 reduced the level of gluten in the bread to below 20 ppm (the FDA threshold for “gluten free” labeling). Finally, the gluten-degrading ability of Kuma030 was tested directly in a wheat beer, since wheat beers demonstrate comparatively high gluten levels²⁴. Beer was incubated with Kuma030 at 37° C. or 4° C. at two enzyme concentrations. Samples were taken at various timepoints and the concentration of remaining gluten was quantified. We found that incubation of beer, which demonstrated a gluten concentration of ˜764 ppm, with Kuma030 decreased the gluten level to below 20 ppm by only 5 minutes (FIG. 4B). The rapidity of this effect is particularly important since liquids empty through the stomach considerably faster than solids²⁵. Surprisingly, Kuma030 significantly reduced the gluten load of wheat beer even at 4° C., as incubation with the Kuma030 at 700 μg mL⁻¹ reduced the gluten levels to below 20 ppm by 5 minutes.

At this time, the only therapy for celiac disease is a lifelong strict gluten free diet. Oral enzyme therapy has been considered an attractive treatment option for CD since the identification of PQ-rich immunogenic gliadin epitopes that stimulate the immune response³. A useful characteristic of any oral enzyme therapeutic for CD is the ability to break down immunogenic peptides in gastric conditions, since the inflammatory immune response to gliadin occurs immediately upon entering the intestine²⁶. Gluten challenge studies in CD patients have shown that the ingested gluten load must be kept at 10 mg or less in order to prevent intestinal damage^27,28. Indeed, the FDA currently mandates that any food labeled as “gluten free” must demonstrate less than 20 ppm gluten, since strict adherence to this standard is predicted to result in a daily ingestion of 10 mg or less. Thus, the accidental ingestion of 1 g of gluten (approximately the amount of gluten present in a crouton) must be reduced by 99% or greater in the gastric compartment in order to prevent the intestinal damage and symptoms that would arise from gluten exposure. There is therefore a clear need for glutenases that can rapidly destroy immunogenic gliadin epitopes in gastric conditions. In a bread slurry model representing ingestion of 4 g of gluten, Kuma030 was found to degrade >99.8% of the gliadin load in 30 minutes at a 1:160 w:w ratio. Additionally Kuma030 specifically destroys peptides with the PQ dipeptide motif, which is commonly found throughout the immunogenic regions of gluten. Indeed. Kuma030 is capable of degrading all immunodominant peptides tested, and gliadin treated with Kuma030 failed to stimulate IFN-γ production by all T cell lines tested, which is significant since CD patients demonstrate a myriad of responses to different immunogenic epitopes.

REFERENCES FOR EXAMPLE 1

• 1. Rubio-Tapia, A., Ludvigsson, J. F., T. L., Mu, J. A. & Everhart, J. E. The prevalence of celiac disease in the United States. Am J Gastroenterol 107, 1538-1544; quiz 1537, 1545 (2012).
• 2. Catassi, C., Gatti, S. & Lionetti, E. World perspective and celiac disease epidemiology. Dig Dis 33, 141-146 (2015).
• 3. Sollid, L. M. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2, 647-655 (2002).
• 4. Gordon, S. R., et al. COMPUTATIONAL DESIGN OF AN alpha-GLIADIN PEPTIDASE. J Am Chem Soc (2012).
• 5. Richter, F. Leaver-Fay, A., Khare, S. D., Bjelic. S. & Baker, D. De novo enzyme design using Rosetta3. PLoS One 6, e19230 (2011).
• 6. Shan, L., et al. Structural basis for gluten intolerance in celiac sprue. Science 297, 2275-2279 (2002).
• 7. Shan, L. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. Journal of Proteome Research (2005).
• 8. Sollid, L. M., Qiao, S. W., Anderson, R. P., Gianfrani. C. & Koning, F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 64, 455-460 (2012).
• 9. Tye-Din, J. A., et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2, 41ra51 (2010).
• 10. Arentz-Hansen, H., et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 191, 603-612 (2000).
• 11. Arentz-Hansen, H., et al. Celiac lesion cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 123, 803-809 (2002).
• 12. Chang, J. H., et al. A novel placement method of the Bravo wireless pH monitoring capsule measuring intragastric pH. Dig Dis Sci 54, 578-585 (2009).
• 13. Lupo, A., Roebuck, C., Walsh, A., Mozola, M. & Abouzied, M. Validation study of the Veratox R5 rapid ELISA for detection of gliadin. J AOAC Int 96, 121-132 (2013).
• 14. Moron, B., et al. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. Am J Clin Nutr 87, 405-414 (2008).
• 15. Landeaho, M. L., et al. The Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients with Celiac Disease. Gastroenterology (2014).
• 16. Bethune, M. T., Strop, P., Tang, Y., Solid, L. M. & Khosla, C. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 13, 637-647 (2006).
• 17. Ehren, J., Govindarajan, S., Moron, B., Minshull, J. &. Khosla, C. Protein engineering of improved prolyl endopeptidases for celiac sprue therapy. Protein Eng Des Sel 21, 699-707 (2008).
• 18. Siegel, M., et al. Rational design of combination enzyme therapy for celiac sprue Chem Biol. 13, 649-658 (2006).
• 19. Gass, J., Bethune, M. T., Siegel, M., Spencer, A. & Khosla, C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133, 472-480 (2007).
• 20. Petersen, J., et al. T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat Struct Mol Biol 21, 480-488 (2014).
• 21. Camarca, A., et al. Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease, J Immunol 182, 4158-4166 (2009).
• 22. Pera, P., et al. Influence of mastication on gastric emptying. J Dent Res 81, 179-181 (2002).
• 23. Siegel, A., et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials, Dig Dis Sci 57, 440-450 (2012).
• 24. Picariello, G., et al. Proteomics, peptidomics, and immunogenic potential of wheat beer (weissbier). J Agric Food Chem 63, 3579-3586 (2015).
• 25. Houghton, L. A., et al. Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology 94, 1285-1291 (1988).
• 26. Castillo, N. E., Theethira, T. G. & Leffler. D. A. The present and the future in the diagnosis and management of celiac disease. Gastroenterol Rep (Oxf) 3, 3-11 (2015).
• 27. Catassi, C., et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 85, 160-166 (2007).
• 28. Akobeng, A. K. & Thomas, A. G. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 27, 1044-1052 (2008).

EXAMPLE 2

Computationally designed enzymes were then produced and tested for their ability to break down immunogenic gliadin peptides. Mutations that were shown to improve the ability of the enzyme to target relevant peptides were then combined and tested in an iterative process to further increase activity. More recently, design has been extended to the binding pocket to prefer either L or Q amino acids. This engineering effort has greatly increased activity on peptides containing a PQL or PQQ tripeptide, which are located within the core epitope of virtually all immunogenic gliadin peptides.

Several Kuma010 variants are used. The specific mutational differences, and their relative effects on activity, are listed in Table 6 below.

TABLE 6
			Activity
			Improvement
Variant	Backgrounda	Mutationb	over Backgroundc
Kuma010	Kumamolisin-As	V119D	116x
		S262K
		N291D
		D293T
		G319S
		D358G
		D368H
Kuma020	Kuma010	G358S	7-19x (PQL)
		I463T	15-35x (PQQ)
Kuma021	Kuma020	D399Q	1-2x (PQL)
		A449Q	1.2-2.5x (PQQ)
Kuma030	Kuma021	K262E	1.2-2x (PQL)
		E267T	1.2-2x (PQQ)
		S354Q
Kuma031	Kuma030	GSTENLYFQSGALEHHHHHH	No change (PQL);
		(SEQ ID NO: 139)	production mutant
		Deleted from C-terminus
Kuma032	Kuma031	P171R	No change (PQL);
		H172R	production mutant
Kuma040	Kuma010	S319A	35-50x (PQL)
		H368F	30-40x (PQQ);
		D399Q	Kuma030 is 2-fold
		A449Q	more active on
		I463T	PQQ, and 2-fold
			less active on
			PQL, than
			Kuma040
Kuma041	Kuma040	GSTENLYFQSGALEHHHHHH	1.0-1.2x (PQL)
		(SEQ ID NO: 139)
		Deleted from C-tetminus
Kuma042	Kuma041	P171R	1.2-1.5x (PQL)
		H172R
Kuma050	Kuma021	K262E	1.5-2x (PQL)
		E267T	0.01-0.2x (PQQ)
		S354Q
		L270V
		T463I
Kuma060	Kuma030	G320M	In bread assays.
			Kuma060 is about
			twice as active as
			Kuma030
Kuma061	Kuma060	GSTENLYFQSGALEHHHHHH	about same
		(SEQ ID NO: 139)	activity as
		Deleted from C-terminus	Kuma060.
Kuma062	Kuma061	P171R	NDd; about same
		H172R	activity as
			Kuma060.
Kuma070	Kuma040	G320M	2-3x (PQL)
			2-4x (PQQ)
Kuma071	Kuma070	GSTENLYTQSGALEHHHHHH	NDd; about 0.2X as
		(SEQ ID NO: 139)	active as Kuma070
		Deleted from C-terminus
Kuma072	Kuma070	GSTENLYQSGALEHHHHHH	about 0.7X as
		(SEQ ID NO: 139)	active as Kuma070;
		Deleted from C-terminus
		P171R
		H172R
aThe specific Kuma010 variant that served as a background upon which the listed mutations were made.
bMutational positions are denoted relative to the full-length Kuma010 enzyme.
cActivity Improvement was calculated for each variant as a fold increase in activity relative to that of the ″background″ enzyme:, the template enzyme used to make that variant. Activity was measured on one or more of the following substrates: a fluorescent-labeled PQPQLP (SEQ ID NO: 156) substrate, the 33mer5 (contains PQL) or 26mer6 (contains PQQ) peptides, or DQ2.5-glia-α1a (contains PQL) or DQ2.5-glia-ω1 (contains PQQ)7. It is important to note that since hundreds of Kuma010 variants were testes, it would have been impractical to obtain kinetic constants for each mutant, thus the fold improvement numbers shown here are estimates instead of definitive numbers. The fold improvement numbers presented here are calculated from the amount of peptide degradation product detected in the degradation assay by LC-MS,
dND: not determined. The activities of leads Kuma060, Kuma061, and Kuma062; and Kuma070, Kuma071, and Kuma072; were compared directiy to each other in bread or meal degradation assays instead of by assessment of individual peptide degradation in order to confirm that no decrease in enzymatic activity occurred upon loss of the His tag. The ability of Kuma070 to break down PQL- and PQQ-containing peptides was compared to Kuma040 as discussed below.

Kuma020, Kuma021, and Kuma030

The active site of Kuma010 underwent further design effort to improve activity against substrates containing either PQL or PQQ tripeptides. Engineering efforts identified the mutations G358S and I463T as important contributors to increased activity. The G358S mutation was a refinement to a previous mutation made at this site in Kuma010. The I463T mutation eliminated the steric hindrance encountered in the P1′ binding pocket when targeting PQL tripeptide motifs, and introduced a new predicted hydrogen bond when PQQ was the substrate⁴. The Kuma010 variant harboring these two mutations demonstrated a very large improvement over the original Kuma010 and was named Kuma020.

Additional mutations were made to this Kuma020 enzyme. D399Q and A449Q were mutations that were located outside of the active site, and so are not predicted to affect binding to the substrate. Instead, these two mutations resulted in new predicted intramolecular hydrogen bonds and were thus predicted to stabilize the enzyme. The resulting variant, Kuma021, showed a further increase in activity.

Three other refinements contributed to the generation of Kuma030 from Kuma021. Kuma030 is described in detail above.

Kuma040 and Kuma050

As an alternative to the mutations listed above, a different set of mutations on the Kuma010 background, S319A and H368F, led to a different active site architecture than the one found in Kuma030. Together these mutations, along with D399Q, A449Q, and I463T, (mutations that also increased activity in Kuma030) make up the Kuma040 variant. Kuma041, Kuma042, Kuma070, Kuma071, and Kuma072 have Kuma040-like active sites, while Kuma031, Kuma032, Kuma060, Kuma061, and Kuma062 have Kuma030-like active sites.

Kuma050 is a Kuma010 variant built on the Kuma021 background with an active site architecture that has more in common with Kuma030 than Kuma040. However, Kuma050 lacks the I463T mutation, and instead harbors a L270V mutation which is predicted to increase its activity against PQL-containing peptides but is predicted to hinder glutamine from accessing the P1′ binding pocket, thereby decreasing activity on PQQ-containing substrates. Accordingly, Kuma050 specifically demonstrates a high level of activity against substrates containing PQL, but not against substrates containing PQQ. The specificity profile of Kuma050 was desired due to the fact that several studies have indicated that the immunodominant 33mer peptide from α-gliadin, which contains several PQL motifs and no PQQ motifs, may be the peptide responsible for the vast majority of the disease in a subset of patients.

The activities of Kuma010, Kuma020, Kuma030, Kuma040, and Kuma050 are shown below for the highly immunogenic 33mer peptide of α-gliadin (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 69) and the 26mer peptide of γ-gliadin (FLQPQQPFPQQPQQPYPQQPQQPFPQ (SEQ ID NO: 70)), which represent PQL- and PQQ-containing peptides, respectively. The appearance of breakdown products over time (LPYPQPQPF (SEQ ID NO: 137) for 33mer peptide; FLQPQ (SEQ ID NO: 138) for 26mer peptide are shown in FIGS. 5A-B.

In both cases, Kuma030 was the dominant enzyme tested, though Kuma040 demonstrated activity almost as potent as Kuma030 especially against the 26mer peptide. As expected, Kuma050 demonstrated good activity on the 33mer peptide, but very poor activity on the 26mer peptide. Compared to Kuma030 and Kuma040, Kuma020 demonstrated a moderate amount of activity on both peptides, consistent with it being a design intermediate as shown above. All variants demonstrate a marked improvement on the original Kuma010 enzyme.

Kuma060 and Kuma070

An additional designed mutation was the mutation G320M. This mutation did not appear particularly promising as it was not predicted to greatly improve activity, and indeed, this residue, while in the active site, does not appear to make direct contact with the gliadin substrate. However, mutation at this position improved activity by 2-4 fold on both substrates. This could be due to slight changes in the Kuma010 backbone incurred by incorporation of the methionine, rendering it into a confirmation that is even more favorable for catalysis. The G320M mutation was incorporated into the Kuma030 and Kuma040 backgrounds to generate enzymes Kuma060 and Kuma070, respectively.

FIGS. 6A-B show the improvement in activity attributed to the G320M mutation on the Kuma040 background in degradation of both immunogenic epitopes DQ2.5-glia-α1a (contains PQL), and DQ2,5-glia-ω1 (contains PQQ).

The KumaXX1 and KumaXX2 Series

With the exception of Kuma021, Kuma010 variants labeled KumaXX1 (ex. Kuma031) correspond to the KumaXX0 variant (ex. Kuma030) in which the C-terminal TEN/protease cut site and 6× His tag have been genetically deleted (GSTENLYFQSGALEHHHHHH (SEQ ID NO: 139)). This tag, which was originally added to the Kumamolisin—As enzyme for high-throughput, easy purification of Kuma010 variants, was removed in certain Kuma010 lead variants as the 6× His tag is not preferable on biologic pharmaceuticals. In general, the removal of this tag did not affect the activity of the enzyme, though His tag removal did appear to result in a slight decrease in the ability of the Kuma070 enzyme (but not the Kuma060 enzyme) to degrade gliadin in a gastric digestion of whole wheat bread.

Kuma010 variants labeled KumaXX2 (ex Kuma032) also lack the His tag, and contain the following additional mutations: P171R and H172R. These mutations don't affect activity of the enzyme, but were incorporated to simplify the purification process. These mutations were introduced into the propeptide domain in the N-terminal region of Kuma010. Since these mutations lie within the propeptide domain, they are not present in the mature, active enzyme. These two mutations fall within the N-terminal region of the protein that sits in the enzyme's active site before cleavage upon exposure to low pH. Since this region is in proximity of the catalytic residues, it is hypothesized that this is the region that undergoes the initial cleavage event upon purification of the Kuma010 enzyme during standard purification procedures. The partially cleaved enzyme N-terminus remains tightly associated with the mature enzyme until the enzyme is exposed to acid. While this initial self-processing during protein purification does not negatively affect activity, it can complicate interpretation of SDS-PAGE analysis by individuals unfamiliar with the Kuma010 enzyme. Thus, in order to simplify the SDS-PAGE profile of purified enzyme, the P171R and H172R mutations were incorporated to reduce the amount of initial N-terminal cleavage that occurs during the protein purification process.

Since KumaXX1 and KumaXX2 variants lack a His tag, they are not purified by Ni affinity chromatography. Instead, these variants are purified by anion exchange chromatography. The following graph demonstrates activity of variants Kuma030, Kuma031, Kuma032, Kuma040, Kuma041, and Kuma042 on immunogenic gliadin peptide DQ2.5-glia-α1a. In this case, all proteins were purified by anion exchange chromatography (even Kuma030 and Kuma040 which harbor an intact 6× Histidine tag), for the sake of comparison. As shown in FIG. 7, P171R and H172R mutations do not appear to negatively affect activity as Kuma032 and Kuma042 demonstrate comparable activity as Kuma030 and Kuma040 (Kuma042 even shows a slight increase in activity against this substrate compared to Kuma040).

Kuma010 variant Kuma062 demonstrates a high amount of activity and it lacks a His tag. A comparison of Kuma062 with Kuma030 and Kuma040 is shown in FIGS. 8A-B (left, detection of full-length DQ2,5-glia-ω1; right, detection of breakdown product):

Enzyme Kinetics

Biochemical parameters were estimated for: Kuma010, Kuma030, Kuma040, and Kuma050. These were estimated using immunogenic gliadin epitopes DQ2.5-glia-α1a and DQ2,5-glia-ω1. Degradation assays were performed with 100 nM enzyme at 37° C. in 100 mM NaOAc pH 4.0 buffer. The below table shows the initial velocity of the degradation reaction as a function of substrate concentration. k_cat and K_M were calculated from this using the Michaelis-Menten equation.

The biochemical parameters of all tested enzymes are shown in Table 7 below.

TABLE 7
			Vmax	Km	Kcat	kcat/Km
Enzyme	[Enzyme]	Substrate	(M s−1)	(mM)	(s−1)	(M−1 s−1)
Kuma010	100 nM	Glia_α1	3.70E−07	4.6	mM	3.7	819
Kuma030	100 nM	Glia_α1	1.74E−06	1.9	mM	17.4	9034
Kuma040	100 nM	Glia_α1	1.49E−06	0.86	mM	16.3	19109
Kuma050	100 nM	Glia_α1	1.42E−06	2.5	mM	14.2	5613
Kuma010	100 nM	Glia_α1	1.22E−07	16.4	mM	1.2	74
Kuma030	100 nM	Glia_α1	2.73E−06	8.4	mM	27.3	3268
Kuma040	100 nM	Glia_α1	2.46E−06	15.3	mM	24.6	1603
Kuma050	100 nM	Glia_α1	2.78E−06	5.0	mM	27.8	56

The mutations made to Kuma030 and Kuma040 greatly increase activity against these peptides, which is promising for their use in detoxifying peptides that are linked to celiac disease. As predicted, the mutations made to Kuma050 increased activity on the DQ2.5-glia-α1a peptide, but not on the DQ2.5-glia-ω1 peptide.

REFERENCES FOR EXAMPLE 2

• (1) Gordon, S. R.; Stanley, E. J.; Wolf, S.; Toland, A.; Wu, S. J.; Hadidi, D.; Mills, J. H.; Baker, D.; Pultz, I. S.; Siegel, J. B. Journal of the American Chemical Society. 2012.
• (2) Wlodawer, A.; Li, M.; Gustchina, A.; Tsuruoka, N.; Ashida, M.; Minakata, H.; Oyama, H.; Oda, K.; Nishino, T.; Nakayama, T. J Biol Chem 2004, 279, 21500.
• (3) Leaver-Fay, A.; Tyka, M.; Lewis, S. M. Lanae, O. F.; Thompson, J.; Jacak, R.; Kaufman, K.; Renfrew, P. D.; Smith, C. A.; Sheffler, W.; Davis, I. W.; Cooper, S.; Treuille, A.; Mandell, D. J.; Richter, F.; Ban, Y. E.; Fleishman, S. J.; Corn, J. E.; Kim, D. E.; Lyskov, S.; Berrondo, M.; Mentzer, S.; Popovic, Z.; Havranek, J. J.; Karanicolas, J.; Das, R.; Meiler, J.; Kortemme, T.; Gray, J. J.; Kuhlman, B.; Baker, D.; Bradley, P. Methods Enzymol 2011, 487, 545.
• (4) Wolf, C.; Siegel, J. B.; Tinberg, C.; Camarca, A.; Gianfrani, C.; Paski, S.; Guan, R.; Montelione, G.; Baker, D.; Pultz, I. S. Journal of the American Chemical Society 2015, 137, 13106.
• (5) Shan, L.; Molberg, O.; Parrot, I.; Hausch, F.; Filiz, F.; Gray, G. M.; Sollid, L. M.; Khosla, C. Science 2002, 297, 2275.
• (6) Shan, L. Journal of Proteome Research 2005.
• (7) Sollid, L. M.; Qiao, S. W.; Anderson, R. P.; Gianfrani, C.; Koning, F. Immunogenetics 2012, 64, 455.
• (8) Arentz-Hansen, H.; Korner, R.; Molberg, O.; Quarsten, H.; Vader, Koov, Y. M.; Lundin, K. E.; Koning, F.; Roepstorff, P.; Sollid, L. M.; McAdam, S. N. J Exp Med 2000, 191, 603.

Claims

1. A polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of seq ID NO: 1, wherein

(a) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and

(b) the polypeptide comprises an amino acid change from seq ID NO: 1 at one or more residues selected from the group consisting of 463A/L/M/Q/R/T/V, 221 D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/T/V, 319A, 320M, 354A/E/Q/R/Y, 358N/S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, 461R, 105H, 171R/A/S, 172R/A/S, 173R/S, 174S, and 456V.

2. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid change from seq ID NO: 1 at one or more residues selected from the group consisting of 463A/L/M/Q/R/T/V, 221 D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/TN, 319A, 320M, 354A/E/Q/R/Y, 358N/S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, and 461R.

3. The polypeptide of claim 1 comprising an amino acid sequence at least 95% identical to the amino acid sequence of seq ID NO: 1.

4. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid change from seq ID NO: 1 at one or more residues selected from the group consisting of 221 D/N/Q/H, 262E, 268S/T/A, 269L/T, 270A/T/V, 319A, 354A/E/Q/R/Y, 358N/S/Q/T, 368F/Q, 399Q, 4025/Q, 406S, 424K, 449E/N/Q, 461R, and 463A/L/M/Q/R/T/V.

5. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid change from seq ID NO: 1 at two or more residues selected from the group.

6. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid change from seq ID NO: 1 at one or more residues selected from the group consisting of 399Q and 449E/N/Q.

7. The polypeptide of claim 6, wherein the polypeptide comprises amino acid changes 399Q and 449Q.

8. The polypeptide of claim 1, wherein the polypeptide comprises amino acid changes 358S and 463T.

9. The polypeptide of claim 1, wherein the polypeptide comprises amino acid changes 262E, 269T, 354Q, 358S, 399Q, 449Q, and 463T.

10. The polypeptide of claim 1, wherein the polypeptide comprises amino acid changes 319A, 368F, 399Q, 449Q, and I463T.

11. The polypeptide of claim 1, wherein the polypeptide comprises amino acid changes 262E, 269T, 270V, 354Q, 358S, 399Q, and A449Q.

12. The polypeptide of claim 1, wherein the polypeptide comprises amino acid changes 262E, 269T, 320M, 354Q, 358S, 399Q, 449Q, and 463T.

13. The polypeptide of claim 1, wherein the polypeptide comprises amino acid changes 319A, 320M, 368F, 399Q, 449Q, and 463T.

14. The polypeptide of claim 1, comprising an amino acid change from seq ID NO: 1 at one or more amino acid positions selected from the group consisting of 105H, 171R/A/S, 172R/A/S, 173R/S, 174S, and 456V.

15. A polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of seq ID NO: 71, wherein

(a) residue 278 is Ser, residue 78 is Glu, and residue 82 is Asp; and

(b) the polypeptide comprises an amino acid change from seq ID NO: 71 at one or more residues selected from the group consisting of 274A/L/M/Q/R/T/V, 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81NTN, 130A, 131M 165A/E/Q/R/Y, 169N/S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, 267V, and 272R.

16. The polypeptide of claim 15, wherein the polypeptide comprises an amino acid change from seq ID NO: 71 at one or more residues selected from the group consisting of 274A/L/M/Q/R/T/V, 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81NTN, 130A, 131M 165A/E/Q/R/Y, 169N/S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, and 272R.

17. The polypeptide of claim 15 comprising an amino acid sequence at least 95% identical to the amino acid sequence of seq ID NO: 71.

18. The polypeptide of claim 15, wherein the polypeptide comprises an amino acid change from seq ID NO: 71 at one or more residues selected from the group consisting of 32D/N/Q/H, 73E, 79S/T/A, 80L/T, 81A/TN, 130A, 165A/E/Q/R/Y, 169N/S/Q/T, 179F/Q, 210Q, 213S/Q, 217S, 235K, 260E/N/Q, 272R, and 274A/L/M/Q/R/T/V.

19. The polypeptide of claim 15, wherein the polypeptide comprises an amino acid change from seq ID NO: 71 at two or more residues selected from the group.

20. The polypeptide of claim 15, wherein the polypeptide comprises an amino acid change from seq ID NO: 71 at one or more residues selected from the group consisting of 210Q and 260E/N/Q.

21. The polypeptide of claim 20, wherein the polypeptide comprises amino acid changes 210Q and 260Q.

22. The polypeptide of claim 15, wherein the polypeptide comprises amino acid changes 169S and 274T.

23. The polypeptide of claim 15, wherein the polypeptide comprises amino acid changes 73E, 80T, 165Q, 169S, 210Q, 260Q, and 274T.

24. The polypeptide of claim 15, wherein the polypeptide comprises amino acid changes 130A, 179F, 210Q, 260Q, and 274T.

25. The polypeptide of claim 15, wherein the polypeptide comprises amino acid changes 73E, 80T, 81V, 165Q, 169S, 210Q, and 260Q.

26. The polypeptide of claim 15, wherein the polypeptide comprises amino acid changes 73E, 80T, 320M, 165Q, 169S, 210Q, 260Q, and 274T.

27. The polypeptide of claim 15, wherein the polypeptide comprises amino acid changes 130A, 131M, 179F, 210Q, 260Q, and 274T.

28. The polypeptide of claim 15, comprising amino acid change 267V.

29. The polypeptide of claim 1, further comprising a histidine tag at the C-terminus of the polypeptide, including but not limited to the amino acid sequence GSTENL YFQSGALEHHHHHH (seq ID NO: 139).

30. The polypeptide of claim 29, wherein the histidine tag comprises a cleavable histidine tag, including but not limited to a cleavable histidine tag comprising the amino acid sequence X_NPQ(L/Q)PX_NHHHHHH (seq ID NO: 131), wherein X_N is an linker of between 1-25 amino acid residues.

31. The polypeptide of claim 30, wherein the cleavable histidine tag comprises the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (seq ID NO: 132).

32. A pharmaceutical composition, comprising the polypeptide of claim 1, and a pharmaceutically acceptable carrier.